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ABSTRACT 
The immune system is a complex network of cells and molecules interacting to preserve the 
integrity and survival of the host by distinguishing self from non-self, and dysregulation of 
immune cells can lead to immunodeficiency, autoimmunity, and cancer. The cytoskeleton is 
essential for several important immune cell functions, including proliferation, movement, 
signaling, and vesicle trafficking. The overall aim of this thesis was to investigate the 
importance of the cytoskeleton for lymphocytes in primary immunodeficiencies. 
In paper I, we investigated the role of the actin-sensing protein MKL1 in B cells, by examining 
samples from three monozygotic triplets with an intronic deletion in MKL1, out of whom two 
had developed Hodgkin lymphoma. MKL1 deficiency has previously been described as 
causing primary immunodeficiency with dysregulation of actin. The intronic deletion in MKL1 
led to increased MKL1 expression, increased MKL1-dependent gene transcription, 
hyperproliferation, dysregulated cytoskeleton, genomic instability, and formation of tumors in 
vivo. Inhibition of MKL1 led to reversion of the phenotype. These results suggest a role of 
MKL1 in the development of Hodgkin lymphoma. 
In paper II, our aim was to investigate the function of LRBA in lymphocytes from a patient 
with LRBA deficiency, presenting with immunodeficiency and autoimmunity. The function of 
LRBA has not been fully clarified previously. LRBA-deficient patient cells accumulated 
vesicles including endosomes, lysosomes, autophagosomes, and lipid bodies. Lipid 
metabolism was altered in patient cells in response to serum starvation. These results suggest 
that LRBA is involved in the response to cell stress, and that the accumulation of vesicles in 
LRBA deficiency may impair the survival and function of immune cells. 
In paper III, we examined the anti-tumor responses of NK cells and T cells in X-linked 
neutropenia, a primary immunodeficiency caused by activating mutations in the actin-
regulatory protein WASp, with increased risk of myelodysplasia. We studied samples from 
patients and mouse models and found that NK cells and T cells in X-linked neutropenia 
displayed normal to increased tumor killing, decreased expression of the exhaustion marker 
KLRG1, increased granzyme B expression, and polarization of actin without stimuli. These 
results suggest that tumor immunosurveillance is not deficient in X-linked neutropenia and that 
the increased risk of malignancy rather is caused by cell-intrinsic aberrations. 
In paper IV, we investigated the development of the T cell receptor repertoire in mouse models 
for Wiskott-Aldrich syndrome, a primary immunodeficiency caused by loss-of-function 
mutations in the actin-regulating protein WASp. We examined thymocytes and spleen T cells 
from young and older mice and found that the thymocyte T cell receptor repertoire was intact 
in young mice but skewed in older mice. The spleen T cell receptor repertoire displayed signs 
of clonal expansions in older mice, suggesting development of an autoimmune response. These 
results suggest that the dependence on WASp for thymic output and the generation of a diverse 
T cell receptor repertoire increases with age. 
In summary, the works presented in this thesis provide evidence for the role of dysregulated 
cytoskeletal responses in the development of primary immunodeficiency and cancer. 
Furthermore, potential drug targets are identified for diseases with increased actin responses or 
lipid dysregulation, and proteins identified as involved in cancer development may also be used 
as markers to screen for in the assessment of disease severity and prognosis.  
  
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Immunförsvaret är ett komplext nätverk av celler och molekyler som samverkar för att skydda 
människan från infektioner och cancer. För att göra detta krävs att immunförsvarets celler kan 
känna igen vad som är kroppsegna, friska celler, och vad som är främmande, 
sjukdomsframkallande celler eller mikroorganismer såsom bakterier och virus. Begreppet 
immunbrist innebär att immunförsvaret är så nedsatt att man får svåra infektioner man inte 
brukar få i normala fall. Detta kan bero på medfödda genetiska mutationer, och kallas då primär 
immunbrist, eller uppstå på grund av immundämpande behandlingar eller infektioner som HIV, 
och kallas då sekundär immunbrist. I denna avhandling har jag undersökt cellskelettets roll för 
en viss typ av immunceller i primära immunbristsjukdomar. Cellskelettet är cellernas inre 
struktur som hjälper dem att utföra många viktiga funktioner, såsom att växa och dela på sig, 
röra på sig, vidarebefordra signaler inne i cellen, och transportera saker inne i cellen. 
I artikel I undersökte vi immunceller från tre enäggstrillingar födda 1945 varav två utvecklat 
en cancerform som heter Hodgkins lymfom. Alla tre trillingar hade en mutation i proteinet 
MKL1 som är viktigt för regleringen av cellskelettet, och brist av det här proteinet hade tidigare 
hittats i en primär immunbristsjukdom. Vi ville därmed undersöka om dessa trillingar också 
hade immunbrist och om det var orsaken till att de hade utvecklat cancer. Vi hittade istället att 
immunceller från trillingarna hade mer mängd än förväntat av proteinet MKL1 och att detta 
ledde till att cellerna växte snabbare, hade ett onormalt cellskelett, hade 
kromosomförändringar, och att cellerna bildade tumörer när vi injicerade dem i möss. Dessa 
fynd talar för att mutationen vi hittat i trillingarnas immunceller kan ha orsakat Hodgkins 
lymfom. Denna information skulle eventuellt kunna användas för att utveckla nya behandlingar 
och diagnostiska metoder för cancer. 
I artikel II undersökte vi celler från en patient med primär immunbrist orsakad av brist på 
proteinet LRBA. Man har tidigare beskrivit andra patienter med denna immunbrist, men inte 
lyckats klargöra proteinets funktion i immunceller. Vi fann att patientceller som saknade 
proteinet LRBA samlade på sig mer än normalt av en typ av vätskeblåsor som finns inne i 
cellen och bland annat används för förvaring, transport eller nedbrytning av cellmaterial. 
Dessutom påverkades patientcellernas sammansättning av fettmolekyler annorlunda när de 
utsattes för svält. Dessa fynd talar för att proteinet LRBA är involverat i cellernas svar på stress 
och att brist på detta protein kan leda till försämrad överlevnad och funktion hos 
immuncellerna. 
I artikel III undersökte vi immunceller i en primär immunbristsjukdom som orsakas av 
överaktivitet av ett protein som heter WASp och som är viktigt för regleringen av cellskelettet. 
Sjukdomen kallas ”X-bunden brist på neutrofiler” (neutrofiler är en viss typ av vita 
blodkroppar) eftersom genen som kodar för proteinet WASp finns på X-kromosomen, och 
leder till infektioner och ökad risk för cancer. Vi hade tillgång till prover från både patienter 
och musmodeller och vårt mål med projektet var att undersöka förmågan att bekämpa cancer 
hos en viss typ av immunceller i denna sjukdom. Vi hittade att immuncellerna hade bevarad 
förmåga att bekämpa cancer, och i vissa fall till och med ökad förmåga. Deras cellskelett var 
dessutom överaktivt. Dessa fynd talar för att den ökade risken för cancer i denna 
immunbristsjukdom inte beror på nedsatt cancerbekämpningsförmåga hos immuncellerna, 
utan sannolikt på grund av orsaker inne i cancercellerna. 
I artikel IV undersökte vi utvecklingen av en viss typ av immuncell i musmodeller för Wiskott-
Aldrich syndrom, en primär immunbristsjukdom som orsakas av brist på proteinet WASp. 
Patienter med denna immunbristsjukdom får svåra infektioner, men immunförsvaret hos 
patienterna kan även vända sig mot frisk vävnad, vilket kallas för autoimmunitet. Vårt mål var 
att undersöka om en normalt bred repertoar av immunceller kunde bildas i Wiskott-Aldrich 
syndrom, eftersom en bred repertoar är viktigt för immunförsvarets förmåga att försvara sig 
mot många olika typer av infektioner. Vi fann att unga möss kunde bilda en normal 
cellrepertoar men att denna förmåga försämrades hos äldre möss med brist på proteinet WASp. 
Vi såg även tecken till autoimmunitet i cellrepertoaren hos de äldre mössen. Dessa fynd talar 
för att behovet av proteinet WASp för utvecklingen av en bred och normal repertoar ökar med 
åldern. 
Sammanfattningsvis visar jag i denna avhandling ett antal exempel på vikten av ett normalt 
fungerande cellskelett i immunförsvaret och att felreglering av cellskelettet är involverat i både 
immunbrist och cancer. I framtiden kan man eventuellt vidareutveckla behandlingar för 
immunbrist och cancer med läkemedel som justerar cellskelettets funktion, eller använda 
cellskelettproteiner som markörer för cancerutveckling. 
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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
Our human bodies are highly complex organisms fine-tuned to keep us alive and produce 
offspring. For this matter, we have during the course of evolution developed sophisticated 
biological processes for e.g. the consumption of food and water, breathing oxygen, and 
interacting with other individuals. These basic needs require us to expose our bodies to the 
environment, constantly putting us at risk of harm from injuries and diseases both infectious 
and non-communicable, further influenced by varying genetic susceptibility to disease.  
To prevent diseases and keep our complex system of tissues and organs healthy and operative, 
we have to preserve the integrity of the most fundamental structural and functional unit of the 
body: the cell. Cells are the smallest units of life and can differentiate to give rise to a wide 
variety of tissues. In humans and other organisms, the immune system works as a defense 
against both extrinsic and intrinsic threats to cellular health. Comprised of a wide range of cells 
and molecules, it constantly surveils the body, and depending on the nature of a potential threat, 
different types of immune responses can be mounted. 
Around 1400 different pathogens, including bacteria, viruses, parasites, and fungi, are known 
to cause disease by infecting humans either extracellularly or intracellularly (1). Furthermore, 
healthy host cells can transform into cancerous cells, leading to different types of cancer 
depending on the cell origin. Over 100 different types of cancers have been described and as a 
disease group cancer acts as one of the leading causes of death worldwide (2). Immune cells 
can limit cancer cell development in a process called immunosurveillance. In its essence, the 
crucial task of the immune system is to distinguish self from non-self: to combat infections and 
cancer strongly and efficiently but leave healthy tissues unharmed. 
The immune system of humans and other vertebrates consists of two major branches: innate 
immunity that responds swiftly and coarsely, and adaptive immunity that requires more 
stimulation cues but acts highly specific once activated. Although the cells involved in these 
respective branches are diverse, they originate from the same cell type residing in the bone 
marrow: hematopoietic stem cells, who give rise to hematopoiesis (from Greek αἷμα, "blood", 
and ποιεῖν, "to make"), the process of blood cell production. 
1.1.1 Hematopoiesis and blood cell types 
Blood is composed of blood plasma and blood cells, i.e. erythrocytes, thrombocytes, and 
leukocytes. All blood cells originate from hematopoietic stem cells in the bone marrow (Figure 
1) but mature in different parts of the body depending on the cell type. 
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Figure 1. Hematopoietic cells and their lineages. All blood cells originate from hematopoietic stem cells residing in the bone 
marrow. B and T cells represent the adaptive immune system and myeloid cells together with NK cells represent the innate 
immune system. Thrombocytes are important for hemostasis and erythrocytes transport oxygen; however, these cells also have 
functions in the immune system. N.B. that this figure is simplified: several progenitors, alternate cell types and non-conventional 
cells have been omitted. 
Erythrocytes are the main oxygen transporters in the body and make up 35–50 % of the blood 
volume, amounting to 3,9–5,7 x 1012 cells/L (3, 4). Apart from delivering oxygen to tissues, 
erythrocytes have immunological functions such as clearing immune complexes from the 
circulation and modulating the innate immune system (5, 6). Furthermore, the erythrocyte cell 
membrane contains several blood group antigensA, highly important in the field of transfusion 
medicine and obstetrics as blood group incompatible transfusions or pregnancies can cause 
severe immune reactions. 
Thrombocytes are important for hemostasis, i.e. the process of controlling bleeding, but also 
take part in immune responses by e.g. expressing Toll-like receptors (TLRs; see section 1.1.2.2) 
and secreting immunomodulatory substances (7). 
Leukocytes are the main cell type of the immune system and comprise several cells of distinct 
functionalities, divisible into two major lineages: myeloid cells (largely corresponding to the 
innate immune system) and lymphocytes (where B and T cells represent the adaptive immune 
system). Myeloid cells develop from myeloid progenitor cells and include granulocytes, mast 
cells, dendritic cells, and macrophages. Lymphocytes develop from lymphoid progenitor cells 
and include B cells, T cells, and natural killer (NK) cells (Figure 1). Leukocytic cell counts in 
blood are displayed in Table 1 (8). 
Non-conventional immune cells bearing properties of both innate and adaptive immunity 
include B1 cells, marginal zone B cells, γδ T cells, and natural killer T cells; however, these 
cells remain outside of the scope of this thesis and will not be described in-depth. 
 
A Karl Landsteiner was awarded the Nobel Prize in 1930 for his discovery of blood groups. 
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Cell count (x 109/L) 
 Males Females 
Total leukocytes 3,39–9,37 3,63–8,87 
– Neutrophils 1,58–6,22 1,74–5,86 
– Eosinophils 0,03–0,38 0,03–0,36 
– Monocytes 0,11–0,55 0,11–0,44 
– Lymphocytes 0,68–2,72 0,73–2,87 
— B cells 0,07–0,44 0,08–0,46 
— T cells 0,36–1,94 0,43–2,09 
— NK cells 0,11–0,73 0,09–0,65 
Table 1. Leukocyte blood counts in adult males and females. Numbers are based on 90 % confidence intervals with outliers 
removed, including adults of ages 40–79 years (8). 
1.1.2 Innate immunity 
The main purpose of the innate immune system is to quickly respond to threat, by identifying 
and removing foreign substances, recruiting other more specific cells, activating complement 
proteins, and presenting antigens to the adaptive immune system. This is accomplished by an 
elaborate system of barriers, molecules, and cells. A central process initiated by innate immune 
cells as a response to harm is called inflammation (from Latin inflammare, “to set on fire”) and 
involves the cardinal signs heat (calor), pain (dolor), redness (rubor), swelling (tumor), and 
loss of function (function laeasa). Swelling, redness, and heat is the result of increased blood 
flow necessary for the delivery of cells and molecules to and from the affected area; pain and 
loss of function serves to alert the host and facilitate healing.  
1.1.2.1 Barriers prevent pathogenic microbes from entering the body 
In a highly simplified form, the human body can be likened to a tube with two orifices (the 
mouth and anus, openings of the gastrointestinal tract) and two cavities (the respiratory and 
urogenital tracts) (Figure 2). The external side of the body is covered with skin and the internal 
sides have a mucosal surface. As these sides are exposed to the environment, the first line of 
the body’s defense are these physical barriers, preventing entry of pathogens to the body. 
 
Figure 2. The human body. A schematic figure illustrating how the human body is exposed to the environment, displayed as 
a sagittal section. As the skin (S), respiratory tract (R), gastrointestinal tract (GI), and urogenital tract (UG) are potential entry 
points for pathogens, these barriers serve as the first line of defense of the body and have developed several features for this 
matter. 
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Mechanical processes, such as peristalsis of the gastrointestinal tract or movement of cilia in 
the respiratory tract, also aid in removing potential infectious threats. Mucosal surfaces produce 
mucus that contain antimicrobial compounds. Acidic compounds are created in the stomach, 
vagina, and skin, acting as chemical barriers capable of destroying pathogens. 
Furthermore, several anatomical areas are populated by commensal microorganisms, forming 
the human microbiome. These normally non-pathogenic microorganisms inhibit pathogens 
either directly by secreted compounds or indirectly by competition for space and nutrients. The 
common gut bacterium Escherichia coli resides in the intestine, producing and secreting a 
cytotoxic compound called colicin, capable of killing other bacterial cells (9). A clinically 
relevant scenario illustrating the mechanisms of protective microbiota is when E. coli and other 
commensal gut bacteria are eradicated by broad-spectrum antibiotic treatments, which can lead 
to overgrowth of Clostridium difficile, a bacterium normally residing in the gut of 2–12 % of 
the population (10, 11), potentially causing mild to severe (even life-threatening) diarrhea. 
1.1.2.2 Initiation of the innate immune response 
When pathogens overcome the first line of defense and enter the body, they can be recognized 
by innate immune cells resident in the tissues infected. In most cases, the first cells to respond 
in the infected tissue are macrophages and dendritic cells (Figure 3). They do so by the 
expression of several different pattern recognition receptors (PRRs), able to detect molecules 
associated to harmful events and trigger an immune response based on this. The patterns 
recognized by PRRs can be grouped into pathogen-associated molecular patterns (PAMPs) and 
danger-associated molecular patterns (DAMPs), depending on their origin: PAMPs are 
associated with infectious microbes and DAMPs are molecules originating from damaged host 
cells. PRRs include TLRsB, C-type lectin receptors, NOD-like receptors, and RIG-I-like 
receptors, and these receptors can either be membrane-bound or cytoplasmic (12). The classical 
prototype for PAMPs is the bacterial toxin lipopolysaccharide (LPS), a potent molecular trigger 
of the inflammatory response via TLR4 (13). 
When macrophages encounter pathogens, they can engulf them by the process of 
phagocytosisC (from Greek φαγεῖν, “to eat”, and κύτος, “cell”) via several phagocytic receptors 
including TLRs. Furthermore, the sensing of pathogens by PRRs activate several intracellular 
pathways in macrophages, leading to the production of inflammatory cytokines including 
interleukin (IL)-1, IL-6, IL-12, tumor necrosis factor (TNF), and CXCL8 (14). IL-1 and TNF 
activate the vascular endothelium, allowing for increased blood flow and permeability to the 
infected tissue, and induce fever. IL-6 induces the so-called acute-phase reaction in the liver, 
leading to the specialized production of proteins necessary in the inflammatory response. IL-
12 stimulates NK cells and T cells (see sections 1.1.2.3 and 1.1.3.4, respectively). CXCL8 is a 
 
B Bruce Beutler and Jules Hoffman were awarded one half of the Nobel Prize in 2011 for their work on TLRs 
(the other half was awarded to Ralph Steinman, see footnote D). 
C First described by Ilya Ilyich Mechnikov, awarding him the Nobel Prize in 1908. 
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chemokine important for the recruitment of neutrophils to the site of infection. Neutrophils are 
the most abundant type of leukocyte in blood (Table 1) and of major importance in the acute 
inflammatory response by their potential to phagocytose and excrete radical oxygen species 
and other antimicrobial compounds. 
Dendritic cellsD function similarly to macrophages in the early immune response to pathogens, 
with phagocytosis as a central feature. However, instead of remaining in the infected tissue, 
activated dendritic cells can migrate to nearby lymph nodes where they present antigens from 
the ingested microbes to T cells in the adaptive immune system (Figure 3). 
NK cells are lymphocytes, but unlike B and T cells, they belong to the innate immune system. 
Their main function is to eliminate tumor cells and virally infected cells. Constituting a central 
part of paper III, they will be described in depth in the following section. 
 
Figure 3. Initiation of the innate immune response. When pathogens enter the tissue, pathogen recognition receptors on 
resident macrophages and dendritic cells detect pathogen-associated molecular patterns, triggering phagocytosis and the 
production of inflammatory cytokines. These cytokines induce dilation of vessels and increase vascular permeability, 
facilitating the delivery of cells and plasma proteins to the infected tissues. Neutrophils are recruited to the tissue by chemokines 
also produced by macrophages and dendritic cells. Dendritic cells migrate to nearby lymph nodes to present antigens from the 
ingested microbes to T cells, initiating the adaptive immune response. 
1.1.2.3 NK cells take part in the immune response against intracellular threats 
NK cells belong to a group of lymphocytes called innate lymphoid cells (ILCs), also including 
ILC1s, ILC2s, and ILC3s. By their distinct cytokine responses when activated, they correspond 
to T cells of the adaptive immune system (cytotoxic T cells, T helper (TH) 1, TH2, and TH17 
cells, respectively; more on T cells in section 1.1.3.4), however, considered part of the innate 
immune system as they lack certain features of adaptive immunity cells, in that they do not 
express adaptive antigen receptors or undergo clonal expansion (15). NK cells in this way 
 
D Ralph Steinman was awarded one half of the Nobel Prize in 2011 for his work on the central role of dendritic 
cells in the initiation of the adaptive immune response. 
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complement the response to intracellular pathogens and tumor cells by cytotoxic T cells. The 
study of NK cell immunodeficiencies has demonstrated that NK cells specifically are needed 
for infections with certain viruses that escape T cell cytotoxicity, in particular herpesviruses 
(16). 
NK cells develop from common lymphoid progenitors in the bone marrow (Figure 1). NK cell 
precursors committed to the NK cell lineage are identified by their expression of the common 
β chain of the IL-2 and IL-15 receptors, these cytokines being of central importance for NK 
cell development (17-19). During the transition from immature to mature, NK cells typically 
acquire expression of CD16 (also known as FcγRIII, a receptor important for antibody-
dependent cellular cytotoxicity (ADCC), see below), CD56, and several NK cell-specific 
receptors (17, 20, 21). However, the development of NK cell in humans is complex to study, 
and it remains unclear if the development is strictly linear or if many different precursor cells 
can develop into mature NK cells in a more branched manner (22).  
NK cell receptors can be grouped into activating and inhibitory receptors. Activating receptors 
include CD16, NKG2D, and NKp46; inhibitory receptors include killer cell immunoglobulin-
like receptors (KIRs), killer cell lectin-like receptor subfamily G member 1 (KLRG1), and 
NKG2A (23) (Figure 4).  
CD16 is a receptor for the constant region of immunoglobulin (Ig) G, and when binding 
antibody-coated cells, crosslinking of CD16 can initiate ADCC, a key function of NK cells in 
the killing of intracellular pathogens or tumor cells (24). NKG2D recognizes ligands 
homologous to major histocompatibility complex (MHC) class I molecules (corresponding to 
human leukocyte antigen (HLA)-A, -B, and -C; more on these molecules in section 1.1.3.4), 
thus activating NK cells when self-proteins are upregulated due to virus infection or cancer 
(25). NKp46 is an activating receptor recognizing ligands associated to a variety of intracellular 
pathogens, including influenza virus and cells infected by Mycobacterium tuberculosis (26). 
KIRs are inhibitory NK cell receptors recognizing MHC/HLA molecules (27, 28); healthy 
nucleated cells expressing MHC class I will not activate NK cells. However, as both virally 
infected cells and tumor cells have been shown to downregulate MHC class I as a means of 
escaping T cell-driven immunity (29, 30), this so-called “missing self” recognition by NK cells 
is essential for the immune response in these cases (31, 32). KLRG1 is an inhibitory NK cell 
receptor that binds to cadherins, a class of cell adhesion molecules present on healthy tissue 
(33). Loss of KLRG1 inhibition in e.g. malignant cell transformation thus leads to MHC-
independent “missing self” recognition and NK cell activation (34). KLRG1 is also expressed 
by antigen-experienced T cells and is associated to lack of proliferative capacity (35). NKG2A 
belongs to the same family of NK cell receptors as the activating receptor NKG2D, however, 
NKG2A initiates inhibitory pathways by recognition of its ligand, the non-classical MHC class 
I molecule HLA-E (36). 
Activated NK cells have two types of effector function: cytotoxicity and cytokine secretion 
(Figure 4). NK cell cytotoxicity is mediated by secretion of lytic granules and signaling through 
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death receptor pathways. Lytic granules secreted by NK cells contain several cytotoxic and 
proteolytic proteins, including perforin and granzyme, forming pores in the membrane of target 
cells and inducing apoptosis (37, 38). Death receptor signaling induced by NK cells are 
mediated by members of the TNF family of cytokines, including Fas ligand and TNF-related 
apoptosis-inducing ligand, leading to apoptosis of target cells (39-41). 
Cytokines secreted by NK cells include interferon (IFN)-γ and TNF, both important for 
immunity against intracellular infections and tumor cells (42-44). IFN-γ affects target cells in 
several ways, including upregulation of MHC/HLA expression, induction of phagocytosis, and 
stimulation of proinflammatory cytokine production (45). Macrophages and dendritic cells 
stimulated by IFN-γ increase their production of IL-12, further stimulating NK cells to secrete 
IFN-γ, resulting in a positive feedback loop (45). 
 
Figure 4. NK cell activation and effector functions. Activation of NK cells is the result of the balance of activating and 
inhibitory signals through a variety of receptors. The main functions of activated NK cells are cytotoxicity and cytokine 
production. A central feature of NK cells is antibody-dependent cellular cytotoxicity (ADCC), initiated by activation through 
CD16. Cytotoxicity is mediated by secretion of lytic granules containing perforin and granzyme, as well as by induction of 
death-receptor signaling by Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL). Cytokines produced by 
NK cells include IFN-γ and TNF. IFN-γ stimulates phagocytosis in macrophages and dendritic cells, as well as inducing IL-12 
production that stimulates NK cells further, resulting in a positive feedback loop.  
1.1.2.4 The complement system and antimicrobial peptides assist the innate response 
Together with the cellular responses in the innate immune system, the so-called complement 
systemE plays an important role in the clearing of pathogens and damaged cells. The 
complement system consists of several plasma proteins that are activated in three distinct but 
convergent pathways: the classical pathway, the alternative pathway, and the lectin pathway. 
The classical pathway requires antibody recognition and is initiated by complement proteins 
including C1, C2, and C4. The alternative pathway is initiated spontaneously on microbial 
surfaces and damaged host cells, and its initiation includes the complement proteins C3, B, and 
D. The lectin pathway is initiated by mannose-binding lectin, binding to carbohydrate 
structures on pathogens, and complement proteins C2 and C4. The three pathways converge in 
the formation of the C3 convertase, crucial for opsonization of pathogens and initiation of the 
 
E Jules Bordet was awarded the Nobel Prize in 1919 for his work on the complement system. The term 
complement was coined in 1899 by Paul Ehrlich, a prominent immunologist of the late 19th century who was 
awarded one half of the Nobel Prize in 1908 for his work on immunity (the other half was awarded to Ilya Ilyich 
Mechnikov, see footnote C). 
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downstream pathway of C5 conversion and formation of the membrane attack complex capable 
of lysing target cells. Cleavage products of complement proteins, such as C3a, C4a, and C5a, 
trigger further innate immune responses including inflammation, recruitment of neutrophils, 
and degranulation of mast cells (46). 
Other molecules involved in the innate immune response include antimicrobial peptides, such 
as defensins and cathelicidins. These peptides are typically amphipathic and cationic, 
facilitating their incorporation into membranes, and have a broad reactivity against bacteria, 
viruses, fungi, and parasites (47). Defensins and cathelicidins are constitutively produced by 
neutrophils and epithelial cells, and expression can be induced further by infectious or 
inflammatory triggers (48, 49). The main effect of antimicrobial peptides has been ascribed to 
membrane pore formation leading to lysis of target cells, however, they may also kill microbes 
by inhibiting their metabolism (50). 
1.1.3 Adaptive immunity 
The adaptive immune response is defined by its potential to produce highly specific responses 
to antigens, as well as creating immunological memory. The receptors of innate immune cells 
are encoded in the germline; receptors of adaptive immune cells are recombined from a variety 
of gene segments, creating vastly diverse receptor repertoires. Immunological memory ensures 
that repeated exposure to pathogens leads to increased capability to resist disease. 
The main cells involved in the adaptive immune response are B and T cells, responsible for 
antibody-mediated and cell-mediated immunity, respectively. These processes largely take 
place in the lymphatic system, consisting of lymphatic vessels, primary (or central) lymphoid 
tissue i.e. the bone marrow and thymus, and secondary (or peripheral) lymphoid tissue i.e. 
lymph nodes and the spleen (Figure 5). Only a minority of circulating lymphocytes are present 
in blood: the absolute majority can be found in the lymphatic system. 
A central feature of the adaptive immune system is the ability to distinguish “self” from “non-
self”: this is acquired through elaborate processes of so-called positive and negative selection 
during B and T cell development, ensuring the retainment of receptors capable of responding 
with enough strength to foreign antigens but not recognizing healthy host tissue. This has 
clinically important implications for immunodeficiency, autoimmunity, cancer, and 
transplantation. 
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Figure 5. The lymphatic system. Lymphatic vessels return fluid (lymph) from peripheral tissues to the central circulation. The 
development of lymphocytes occurs in primary lymphoid tissues (thymus and bone marrow). Mature lymphocytes encounter 
antigen in secondary lymphoid tissues (lymph nodes and spleen). 
1.1.3.1 The genetic process of V(D)J recombination yields extremely diverse B and T cell 
receptor repertoires 
The ability of the adaptive immune system to produce highly specific antigen responses stems 
from the immensely diverse receptor repertoires of B and T cells. In contrast to the germline-
encoded receptors of the innate immune system, B cell receptors (BCRs) and T cell receptors 
(TCRs) are recombined from separate gene segments in their respective gene loci, in a process 
called V(D)J recombinationF. The resulting extreme diversity of genetic sequences leads to a 
capability of BCRs to potentially recognize 1013–1018 different antigens and of TCRs to 
potentially recognize 1015–1020 different antigens (51-54). N.B. that the genetic sequence 
diversity of BCRs and TCRs not necessarily corresponds to the actual number of different 
recognizable antigens; furthermore, the actual receptor repertoire in a given individual is 
restricted by the number of B and T cells present in the body, considerably lower than the 
theoretical number of receptor diversity (at least 1011 of both B and T cells, respectively (55, 
56)). 
V(D)J recombination takes place during the development of B and T cells in the bone marrow 
and thymus, respectively (Figure 5). The BCR and TCR gene loci are arranged according to 
the subunits of the receptors: Ig heavy chain and light chains κ and λ; and α and β chains (as 
well as γ and δ chains, not described further in the scope of this thesis), respectively. For BCR 
Ig heavy chains and TCR β chains, the genes are arranged in so-called variable (V), diversity 
(D), and joining (J) segments; for BCR light chains and TCR α chains, there are only V and J 
segments. 
The recombination of VDJ segments is mediated by enzymes including recombination-
activating genes (RAG) 1 and 2, terminal deoxynucleotidyl transferase (TdT), and Artemis. 
RAG1 and RAG2 bind to recombination signal sequences flanking each segment, creating 
DNA strand breaks that together with Artemis are mended by non-homologous end joining 
(NHEJ), simultaneously excising unused segments (Figure 6) (57, 58). Furthermore, 
 
F Susumu Tonegawa was awarded the Nobel Prize in 1987 for his work on the genetic principle for generation of 
BCR/antibody diversity, 
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inaccuracies are introduced by TdT in the form of the addition of a random number of 
nucleotides between the joined segments, generating junctional diversity that dramatically 
increases the overall receptor diversity (58). 
 
Figure 6. VDJ recombination. Functional B cell receptor (BCR) and T cell receptor (TCR) genes are recombined from gene 
segments in their respective loci. For BCR Ig heavy chains and TCR β chains, the genes are arranged in so-called variable 
(V), diversity (D), and joining (J) segments (their common principle of recombination shown in this figure); for BCR light 
chains and TCR α chains there are only V and J segments, but the mechanism of recombination is the same. Segments are 
flanked by recombination signal sequences (RSSs) targeted by recombination-activating genes (RAG) 1 and 2, inducing 
DNA strand breaks mended by non-homologous end joining by RAG1-2 and Artemis; segments not used are excised. D and 
J segments are recombined first, after which a V segment is joined. Further junctional diversity is added by the enzyme 
terminal deoxynucleotidyl transferase (TdT) by the addition of a random number of nucleotides. 
1.1.3.2 B cells are the effector cells of humoral immunity 
B cells are lymphocytes mainly developing in the bone marrow and spleen and constitute a 
major part of humoral immunity (from Latin umor, “fluid”), i.e. immunity originating from 
molecules in extracellular fluids (this term thus also involves the complement system and 
antimicrobial peptides; see section 1.1.2.4). Their main effector function is the production of 
antibodiesG, soluble forms of their BCR that take part in a wide variety of immune functions. 
The development of B cells originates with common lymphoid progenitors in the bone marrow. 
A central process is the production of a functional BCR, why several developmental stages of 
B cells are tied to V(D)J recombination. Early B cells committed to the lineage start to express 
RAG1, RAG2, and TdT, needed at the subsequent stage when pro-B cells first recombine the 
Ig heavy chain D and J segments and later the heavy chain V segment to the joined DJ segments 
(Figure 7) (59, 60). During the pro-B cell stage, cells start to express the B cell marker CD19 
 
G Nils Jerne was awarded the Nobel Prize in 1984 for his work on antibody immunity, sharing the prize with 
Georges Köhler and César Milstein for their work on the production of monoclonal antibodies. 
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(59). A successfully recombined heavy chain couples with the so-called surrogate light chain, 
assembling the pre-BCR complex also composed of the Igα and Igβ signaling subunits, and 
marks the transition to the pre-B cell stage (61, 62). 
The assembly of and signaling through the pre-BCR complex is the first major checkpoint in 
B cell development and serves three main functions: allelic exclusion, i.e. inhibiting further 
heavy chain recombination to ensure only one heavy chain version per cell is expressed; 
proliferation of functional pre-B cells; and initiation of Ig light chain recombination (63). When 
light chain V and J segments are successfully recombined into a functional light chain (either 
κ or λ), the BCR is assembled and expressed as the membrane-bound antibody IgM (62). 
A functional BCR is the second major checkpoint in B cell development and marks the 
transition to immature B cells. At this stage, several processes are engaged to limit the egress 
of autoreactive B cells from the bone marrow: if the assembled BCR binds with too much 
strength to self-antigens in the bone marrow, the B cell can undergo receptor editing (i.e. 
exchanging the Ig light chain), deletion, or become anergic (64).  
Immature B cells that survive this so-called negative selection leave the bone marrow and 
proceed to become circulating transitional B cells, expressing IgD alongside IgM as well as the 
B-cell activating factor receptor, important for B cell maturation and survival in the periphery 
(51, 65-67). The final maturation stages occur in the spleen, where the majority of B cells 
differentiate into circulating so-called follicular B cells, and some differentiate into marginal 
zone B cells remaining in the spleen (51). 
 
Figure 7. B cell development. Early B cells in the bone marrow start to express recombination-activating genes (RAG) 1 and 
2 as well as terminal deoxynucleotidyl transferase (TdT). During the pro-B cell stage, the immunoglobulin heavy chain is 
recombined from V, D, and J gene segments, and co-receptor CD19 is expressed. A successfully recombined heavy chain 
couples with the surrogate light chain (SLC) to form the pre-BCR, marking the transition to the pre-B cell stage. When the 
immunoglobulin light chain is successfully recombined, the BCR is expressed (as membrane-bound IgM). These immature B 
cells undergo negative selection to minimize the amount of autoreactive B cells egressing from the bone marrow. Transitional 
B cells in the periphery express IgD and mature in the spleen. 
As naïve follicular B cells circulate in the blood and the lymphatic system, they pass through 
follicles in lymph nodes and the spleen. B cells are capable of recognizing a wide variety of 
antigenic structures, including proteins, carbohydrates, and lipids (in contrast to T cells that 
only can recognize protein antigens presented on MHC/HLA molecules; see section 1.1.3.4). 
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If a B cell encounters its cognate antigen, it may become activated and initiate a humoral 
immune response involving the production of secreted antibodies. Antigen responses are 
classified as either T-dependent or T-independent based on if T cell help is needed to activate 
the antibody response of B cells. 
When the BCR binds to its antigen, the BCR complex aggregates, with subunits Igα and Igβ 
transmitting signals and surface molecules CD19 and CD21 acting as co-receptors. CD19 
lowers the threshold for BCR activation and CD21 is a complement receptor, further increasing 
stimulation in the presence of complement C3 fragments (68, 69). Activation-induced 
conformational changes in the BCR complex allow immunoreceptor tyrosine-based activation 
motifs (ITAMs) on Igα and Igβ to become phosphorylated by Src family kinases and bind 
spleen tyrosine kinase (Syk) (70-72). Syk initiates downstream signaling pathways, including 
the activation of Rho GTPases (73, 74), and ultimately activation of transcription factors 
necessary for B cell differentiation and proliferation, including Myc, NFAT and NF-κB (71, 
72). 
Activated B cells undergo clonal expansion and differentiate into plasma cells, able to secrete 
large quantities of antibodies (Figure 8). Depending on if T cell help has been provided, these 
plasma cells may be long-lived or short-lived. T-dependent antigen activation in lymphoid 
follicles leads to the development of so-called germinal centers, microanatomical structures 
where B and T cell interactions lead to the production of class-switched and highly specific 
antibodies. These interactions require follicular TH cell recognition of internalized antigen 
presented on MHC/HLA molecules by B cells, and is mediated by CD40 on B cells binding to 
CD40 ligand on follicular TH cells (75).  
Class switching is the process of changing the constant region of antibodies from IgM to IgG, 
IgA, or IgE, enabling specialization of the immune response as these antibody classes have 
different effector functions. The outcome of this process depends on the cytokine environment 
in the germinal center, influenced by the type of immune response trigger. Class switching is 
mediated by the enzyme activation-induced cytidine deaminase (AID), expressed in germinal 
center B cells (76). AID introduces directed mutations in DNA by the deamination of a cytosine 
base, which becomes uracil, recognized and removed by uracil-DNA glycosylase (77). This 
leads to DNA double-strand breaks in class switch regions of the Ig heavy chain locus, whereby 
the constant region is rearranged and DNA strand breaks are mended by NHEJ (78). 
To increase the antigen specificity of produced antibodies, B cells in the germinal center can 
undergo somatic hypermutation, a process where the antibodies with the highest antigen 
affinity are selected. In the germinal center, follicular dendritic cells present antigen to B cells, 
who require this antigenic stimulation to proliferate. As AID expression is upregulated for 
germinal center B cells, a multitude of random point mutations are introduced in the antibody 
V regions that bind antigen (79). The competition for antigen binding leads to a selective 
pressure on antibody specificity, ensuring that only B cells with high-affinity receptors survive 
the germinal center reaction. 
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B cells that emerge from the germinal centers differentiate into either plasma cells or memory 
B cells. Without T cell help, plasma cells are generally short-lived, however, T-dependent 
antigens generate long-lived plasma cells residing in the bone marrow and capable of producing 
antibodies for an extended period of time (80). Memory B cells remain dormant in the body, 
and rapidly respond to re-exposure to antigen with antibody production, forming a secondary 
response that generally is more efficient than the primary due to the antibodies produced 
already being class switched and affinity maturated (81). 
 
Figure 8. B cell activation and antibody production. When B cells encounter their cognate antigen, they are activated and 
undergo clonal expansion, becoming antibody-secreting plasma cells. T-independent antigen responses result in short-lived 
plasma cells producing IgM antibodies. T cells recognizing internalized antigen presented on B cell MHC/HLA molecules 
provide stimulation by CD40 ligand, resulting in a T-dependent antigen response where B cells undergo class switching and 
somatic hypermutation in the germinal center. The germinal center reaction results in long-lived plasma cells typically 
secreting IgG, IgA, or IgE antibodies. TCR, T-cell receptor; MHCII, major histocompatibility complex class II; CD40L, 
CD40 ligand.  
1.1.3.3 The structure and function of antibodies 
AntibodiesH consist of two heavy chains and two light chains and have one variable antigen-
binding region (Fab) and one constant region (Fc) (Figure 9A). The most crucial parts for 
antigen-binding of the Fab region are called complementarity-determining regions (CDRs) 1-
3, where CDR1 and CDR2 correspond to sequences in the V gene segment and CDR3 spans 
the V(D)J junction of heavy and light chains, constituting the most variable region. AID has 
been shown to specifically concentrate its mutational activity on hotspots in these regions (82).  
 
H Gerald Edelman and Rodney Porter were awarded the Nobel Prize in 1972 for their work on the structure of 
antibodies. 
 14 
As the effector molecule of the B cell response, antibodies can perform a variety of functions, 
including neutralization of pathogens or toxins; complement activation; and recruitment of 
innate cells for phagocytosis, degranulation, and/or cytotoxicity (Figure 9B) (83). The 
functions of the different Ig classes are related to their constant regions and molecular structure. 
Depending on the Ig class, the antibody constant regions bind to different Fc receptors 
expressed by a wide variety of cells; these receptors can be both activating and inhibitory. The 
co-expression of activating and inhibitory Fc receptors by individual immune cells sets a 
threshold for activation and thereby regulates downstream responses depending on the course 
of the immune reaction (84). 
IgM is secreted as a pentamer, facilitating complement activation by providing several binding 
sites for the complement protein C1q (85). IgG can also activate complement, but as it is 
secreted as a monomer, at least two IgG molecules in proximity to each other are required for 
this activation. The main effector functions of IgG are instead neutralization, opsonization, and 
initiation of ADCC (83); IgG can also be transferred over the placenta in pregnancy, providing 
neonatal immunity. IgA is important for mucosal immunity and is secreted as a dimer. IgE is 
important in immunity against parasites, as it binds to Fcɛ receptors on mast cells and induces 
degranulation of histamine-containing granules, also a central mechanism in allergy (86).  
 
Figure 9. Antibody structure and function. (A) Antibodies consist of two heavy chains and two light chains and have one 
variable antigen-binding region (Fab) and one constant region (Fc). Complementarity-determining regions (CDRs) in the 
variable region are highly specific for antigen. (B) Antibody effector functions include the direct neutralization of pathogens or 
toxins; complement activation; and recruitment of innate cells for e.g. phagocytosis or antibody-dependent cellular cytotoxicity 
(ADCC). 
1.1.3.4 T cells are the key mediators of cell-mediated immunity 
T cells are lymphocytes central to the orchestration of a wide variety of immune responses, 
including cell-mediated immunityI against intracellular infections and providing help to e.g. B 
cells, neutrophils, and eosinophils in immunity against extracellular pathogens. The main types 
of T cells are cytotoxic T cells, TH cells, and regulatory T (Treg) cells. The antigen recognition 
 
I Peter Doherty and Rolf Zinkernagel were awarded the Nobel Prize in 1996 for their description of cell-
mediated immunity in the defense against viral infections. 
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of T cells is MHC-restricted, i.e. they can only recognize peptide antigens presented on 
MHC/HLA moleculesJ. 
The T in T cells comes from the thymus, the organ where they develop from common lymphoid 
progenitors that have migrated from the bone marrow. Early thymic progenitors enter the 
thymus in the corticomedullar junction and start migration towards the cortex, during which 
they interact with thymic epithelial cells providing signals for differentiation and survival 
(Figure 10) (87, 88); Notch and Wnt signaling pathways are essential for T cell development 
(89, 90). The different developmental stages of thymocytes are tied to V(D)J recombination of 
the TCR chains, as well as the expression of the T cell co-receptors CD4 and CD8: from double-
negative (DN) through double-positive (DP) to single-positive T cells. 
In humans, early thymic progenitors differentiate through three DN stages, based on their 
expression of surface markers CD38 and CD1a: DN1 identified as CD38-CD1a-; DN2 
identified as CD38+CD1a-; and DN3 identified as CD38+CD1a+ (91). In mice, DN thymocyte 
differentiate through four DN stages, based on the expression of CD44 and CD25: DN1 as 
CD44+CD25-; DN2 as CD44+CD25+; DN3 as CD44-CD25+; and DN4 as CD44-CD25- (92). 
Similar to early B cells, early thymocytes start to express RAG1-2 and TdT to initiate V(D)J 
recombination (89, 91). As thymocytes reach stage DN3, they are committed to the T cell 
lineage and start to recombine their TCR β chain, first by joining of D and J segments, and later 
by the joining of a V segment to the recombined DJ. The TCR β chain couples with the 
invariant pre-TCR α chain, leading to the assembly of the pre-TCR complex also involving the 
TCR co-receptor CD3 and the ζ chain (93, 94). Signaling through a functional pre-TCR 
stimulates proliferation and induces so-called β-selection, i.e. allelic exclusion preventing 
further recombination of TCR β chains, as well as initiates the recombination of the TCR α 
chain (95). 
DN thymocytes become DP thymocytes by the expression of both CD4 and CD8 co-receptors, 
and at around this stage a successful recombination of the TCR α chain leads to the assembly 
of the TCR complex (89). Signaling through the TCR during T cell development is essential 
for the processes of positive and negative selection, whereby TCR recognition of antigen is 
tested on MHC/HLA molecules of thymic epithelial cells as the DP thymocytes migrate 
towards the thymic medulla. T cells with TCRs not recognizing antigen die by neglect (positive 
selection; resulting in MHC-restricted antigen recognition of surviving T cells), and T cells 
with TCRs with too high affinity to self-antigen are forced to undergo apoptosis (negative 
selection), limiting the egress of autoreactive T cells from the thymus (96, 97). As the thymic 
environment itself is not representative of the whole human body, thymic epithelial cells  
 
J Baruj Benacerraf, Jean Dausset and George Snell were awarded the Nobel Prize in 1980 for their discovery of 
MHC molecules. 
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acquire the potential to display a wide variety of tissue-specific antigens to developing T cells 
by the expression of the autoimmune regulator gene (98). 
The absolute majority of thymocytes fail positive and negative selection and thus undergo 
apoptosis: this overproduction reflects how important the sensitive calibration of TCR 
specificity is for the adaptive immune system. Surviving T cells proceed into either the CD4+ 
or CD8+ single-positive lineages, developing into TH cells or cytotoxic T cells, respectively. 
Some T cells destined for negative selection may develop into Treg cells, capable of inducing 
immunosuppressive responses and thus maintaining tolerance to self-antigens in the periphery 
(96). Furthermore, a separate lineage of non-conventional T cells, γδ T cells, may develop from 
common progenitors to αβ T cells in the thymus, bearing invariant antigen receptors and 
potentially taking part in a wide variety of innate-like responses (99). 
 
Figure 10. Human T cell development in the thymus. Early thymic progenitor cells enter through the blood into the 
corticomedullar junction of the thymus, expressing recombination-activating genes (RAG) 1 and 2 as well as terminal 
deoxynucleotidyl transferase (TdT) necessary for subsequent V(D)J recombination of TCR α and β chains. As thymocytes 
migrate through the cortex and medulla, they proceed through developmental stages linked to and named after the presence of 
CD4 and CD8 T cell co-receptors. At the end of the initial double-negative (DN) stages, thymocytes assemble a pre-TCR 
complex consisting of the TCR β chain, a pre-Tα chain, and the co-receptor CD3; signaling through the pre-TCR leads to so-
called β-selection. Double-positive (DP) thymocytes that have functionally rearranged α and β chains form a TCR complex and 
undergo positive and negative selection. The majority of thymocytes undergo apoptosis; the surviving single-positive cells 
develop into either CD4+ T helper cells, CD8+ cytotoxic T cells, or regulatory T cells. 
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Naïve TH cells and cytotoxic T cells circulate the blood and lymph, and being MHC-restricted, 
need to encounter antigen presented on the membrane proteins MHC/HLA class I and II 
molecules (100). MHC class I molecules are expressed on all nucleated cells and consist of an 
α chain and β2 microglobulin, capable of presenting peptide antigens derived from cytosolic 
proteins. In humans, MHC class I corresponds to HLA-A, -B, and -C. MHC class II molecules 
are expressed on professional antigen-presenting cells such as macrophages, dendritic cells, 
and B cells, and consist of an α chain and a β chain. They are capable of presenting peptide 
antigens derived from extracellular internalized proteins and correspond to HLA-DP, -DQ, -
DR, DM, and DO in humans. The MHC genes are the most polymorphic genes in humans (and 
mammals), reflecting evolutionary pressure from infectious diseases and has implications for 
the heritably differential risk of developing diseases related to the immune system (101-103). 
As a naïve T cell recognizes its cognate antigen by its TCR α and β chains, its co-receptor CD4 
(recognizing MHC class II) or CD8 (recognizing MHC class I) will provide additional 
stimulation and signal transduction. Activation-induced conformational changes in the TCR 
complex allow ITAMs on the co-receptor CD3 and the ζ chain to become phosphorylated by 
Lck, a Src family kinase that is non-covalently bound to CD4 and CD8 (104). The 
phosphorylated ITAMs recruit the adaptor protein ZAP-70 (105) (analogous to Syk in BCR 
signaling), initiating downstream signaling pathways, including the activation of Rho GTPases 
(106), and ultimately the activation of transcription factors AP-1, NFAT, and NF-κB, necessary 
for T cell activation and proliferation (107). 
Further regulation of T cell activation comes from the effect of co-stimulatory and inhibiting 
receptors including CD28, cytotoxic T lymphocyte-associated protein 4 (CTLA-4), and 
programmed cell death protein 1 (PD-1)K. CD28 is a T cell co-stimulatory receptor capable of 
recognizing activation-induced molecules on antigen-presenting cells, including CD80 and 
CD86 (also known as B7-1 and B7-2, respectively), leading to amplification of the TCR signal 
(108, 109). CTLA-4 is a T cell inhibitory receptor also capable of recognizing CD80 and CD86, 
suppressing the TCR signal, and is also found in high numbers on Treg cells (110, 111). PD-1 
is an inhibitory receptor recognizing PD ligands on many different cell types, also suppressing 
the TCR signal upon ligation (112). 
When CD8+ cytotoxic T cells are activated by antigen on MHC class I, they kill the antigen-
presenting cell by the secretion of cytotoxic granules (Figure 11A). As in NK cells, the 
cytotoxicity is mediated by perforin and granzyme, forming pores in the membrane of target 
cells and inducing apoptosis (37, 38). In this way, cytotoxic T cells eliminate tumor cells or 
infected cells and limit the spread of disease. 
CD4+ TH cells that are activated by antigen on MHC class II may differentiate into different 
TH subsets depending on the cytokine environment the activation occurs in: the main subsets 
 
K James Allison and Tasuku Honjo were awarded the Nobel Prize in 2018 for their work on cancer therapy based 
on inhibition of CTLA-4 and PD-1 regulation, respectively. 
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are TH1, TH2, and TH17 (other subsets, including TH9 and TH22 (113, 114), will not be 
discussed here). 
TH1 cells stimulate the phagocytic response of macrophages; IFN-γ secreted by TH1 cells 
increases production of reactive oxygen species and nitrous oxide, facilitating the killing of 
phagocytosed bacteria (115, 116). Furthermore, TH1-activated macrophages increase their 
secretion of inflammatory cytokines and the expression of MHC and co-stimulatory molecules 
(117). Differentiation of CD4+ T cells into TH1 cells is induced by IL-12 and IFN-γ (118-120). 
TH2 cells participate in the immune response against parasites by the secretion of IL-4, IL-5, 
and IL-13, stimulating eosinophils, mast cells, IgE production by B cells, and alternative 
activation of macrophages (121); alternative macrophage activation is directed towards tissue 
repair and fibrosis rather than phagocytosis and inflammation (115). Differentiation of CD4+ 
T cells into TH2 cells is induced by IL-4 (122, 123). Dysregulation of the TH2 response has 
been shown in the development of allergic diseases, as cytokine secretion by allergen-activated 
TH2 cells may drive the production of IgE by B cells and induce airway inflammation and 
fibrosis in asthma (124, 125). 
TH17 cells participate in the response to extracellular bacteria and fungi. The secretion of IL-
17 and IL-22 activates leukocytes and epithelial cells to produce antimicrobial peptides and 
cytokines, stimulating inflammation, neutrophils, as well as increasing the barrier integrity of 
epithelial cells (126-128). TH17 differentiation is mainly induced by IL-1, IL-6, and IL-23 as 
well as transforming growth factor β (129, 130). 
Treg cells modulate the immune response by maintaining peripheral tolerance and suppressing 
the activity of other types of T cells. Their suppressive action is in part mediated by the 
secretion of inhibitory cytokines IL-10 and transforming growth factor β (131, 132), but other 
regulatory modes of action include suppression by cytolysis, metabolic disruption, or targeting 
dendritic cells (133). 
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Figure 11. Activation and function of cytotoxic T cells and TH cells. (A) CD8+ cytotoxic T cells recognize antigen presented 
on MHC class I molecules, leading to killing of the antigen-presenting cell by the secretion of cytotoxic granules containing 
perforin and granzyme. (B) CD4+ TH1 cells recognize antigen presented on MHC class II molecules, leading to the secretion 
of IFN-γ that stimulates phagocytosis in the target cell and induces the expression of MHC class II and co-stimulatory 
molecules. (C) Activated TH2 cells secrete cytokines IL-4, IL-5, and IL-13, important for the defense against parasites by the 
stimulation of B cell IgE production and activation of mast cells and eosinophils. IgE antibodies bound to the surface of mast 
cells and eosinophils mediate the release of histamine when binding to their antigen. TH2 cells also stimulate alternative 
macrophage activation, promoting tissue repair and fibrosis. (D) TH17 cells secrete IL-17 and IL-22 that stimulate leukocytes 
and epithelial cells to produce antimicrobial peptides and proinflammatory cytokines, recruiting neutrophils crucial for the 
defense against extracellular bacteria and fungi. 
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1.2 THE CYTOSKELETON 
The cytoskeleton is the main structural component of the cell, composed of a network of 
proteins that are involved in a several essential functions, including preserving the integrity of 
the cell, mediating its connection to surrounding cells and tissues, controlling cell movement, 
and organizing a multitude of intracellular processes in space and time. The main cytoskeletal 
components are actin filaments (also known as microfilaments), microtubules, and 
intermediary filaments, where actin will be described in more depth as it constitutes a major 
part of the works included in this thesis. 
1.2.1 Actin filaments 
Actin filaments take part in a wide variety of cellular functions including movement, 
proliferation, signaling, endocytosis, and secretion, as well as providing a structural network 
for organelles and other intracellular structures. They consist of the protein actin, with a mass 
of 42 kDa, existing in free form as the monomeric globular (G)-actin or in polymeric filaments 
as filamentous (F)-actin (134). The turnover between these forms of actin is highly dynamic 
and regulated by several mechanisms. 
1.2.1.1 Polymerization of actin 
Each actin filament is made up by two parallel F-actin strands intertwined as a double helix; 
the structure is polar with a fast-growing barbed (+) end and a slow-growing pointed (-) end 
(Figure 12A). The first step in polymerization of actin is nucleation, i.e. the formation of actin 
nucleus consisting of three actin monomers, a process which is thermodynamically 
unfavorable; however, when nucleated, further polymerization is facilitated (135, 136). 
Polymerization of G-actin into F-actin is made possible by actin being an ATPase, hydrolyzing 
ATP into ADP at the barbed end as monomers are added; ADP and free actin monomers 
dissociate from the pointed end (137). Rapid turnover of F-actin is necessary for adaptive 
movement of the cell, and polymerization is regulated by several proteins. Actin filament 
treadmilling is the process where the polymerization at the barbed end matches 
depolymerization at the pointed end, a process keeping the filaments at the same length and 
generating force by the consumption of ATP (138).  
1.2.1.2 Subcellular structures of actin filaments 
Several subcellular structures can be formed by actin filaments, including lamellipodia, 
filopodia, stress fibers, focal adhesions, and cortical actin (Figure 12B). These structures 
consist of branched actin networks or cross-linked actin filaments (so-called bundles), 
contributing to different shapes and functions. Lamellipodia are broad cell protrusions on the 
leading-edge of cells, mediating migration, and are rich in branched actin filaments (139); they 
are the main site for actin filament formation in the cell (140). Filopodia (also known as 
microspikes) are thin antennae-like cell protrusions built up by bundles of parallel actin 
filaments, extending from the lamellipodium to sense the environment and mediate migration 
and cell-cell communication (141, 142). Stress fibers are made up of antiparallel actin filaments 
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coupled with myosin, rendering them contractible, and respond to mechanical stress; they can 
be categorized into dorsal and ventral stress fibers, transverse arcs, and the perinuclear actin 
cap (143, 144). Focal adhesions are actin-rich structures mediating binding to the extracellular 
matrix via integrins, attaching the cell to its surroundings and transmitting signals regulating 
migration, proliferation, and gene expression (145). Cortical actin is arranged in a network 
together with actin-binding proteins and myosin, connected to the cell membrane and providing 
shape as well as regulating several events at the cell surface (146). 
 
Figure 12. Actin polymerization and actin filament structures. (A) Globular (G)-actin polymerizes into filamentous (F)-
actin. Two F-actin strands intertwine as a double-helical actin filament with a barbed (+) and pointed (-) end. (B) Actin filament 
bundles and branched networks form lamellipodia, filopodia, stress fibers, focal adhesions, and cortical actin. 
1.2.1.3 Regulation of actin filament dynamics 
As actin filaments are involved in many essential cell processes, its structural dynamics are 
tightly regulated by a group of proteins called actin-binding proteins (ABPs). These ABPs 
control several steps of actin filament assembly, including nucleation, monomer binding, 
branching, cross-linking, capping, severing, and depolymerization (Table 2) (147). Due to its 
connection to Wiskott-Aldrich syndrome protein (WASp), of central importance for papers III 
and IV, the actin-related protein (Arp) 2/3 complex will be described in detail in this section. 
WASp as well as the monomer-binding protein megakaryoblastic leukemia 1 (MKL1; of 
central importance for paper I) will be described in upcoming sections 1.2.2 and 1.2.3, 
respectively. 
Type of regulation Actin-binding protein 
Nucleation Arp2/3 complex, formin 
Monomer binding MKL1, profilin, ADF, cofilin 
Branching Arp2/3 complex 
Cross-linking Filamin, α-actinin, spectrin, transgelin  
Capping Capping protein, gelsolin, tensin 
Severing Gelsolin 
Depolymerization ADF, cofilin 
Table 2. Actin-binding proteins. Examples of actin-binding proteins involved in the regulation of actin filament dynamics. 
Arp, actin-related protein; MKL1, megakaryoblastic leukemia 1; ADF, actin depolymerizing factor. 
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The Arp2/3 complex is a nucleating and branching ABP and consists of seven subunits: Arp2, 
Arp3, and ARPC1-5 (148, 149). Arp2 and Arp3 have structures similar to monomeric actin, 
why binding of the Arp2/3 complex to G-actin initiates nucleation by the formation of an actin 
trimer-like structure, facilitating further polymerization (150). The Arp2/3 complex binds to 
the side of already existing actin filaments, promoting the creation of a branch with a 70° angle 
(150, 151). However, the Arp2/3 complex is in itself not capable of initiating nucleation, and 
typically requires the presence of ATP and so-called nucleation-promoting factors, including 
WASp (152, 153). Arp2/3 is involved in several cellular functions including lamellipodia 
formation; adhesion and podosome formation; phagocytosis; endocytosis; vesicle trafficking; 
and secretion (149). 
1.2.2 Wiskott-Aldrich syndrome protein 
WASp is an actin nucleation-promoting factor uniquely expressed in hematopoietic cells, 
belonging to the WASp family of proteins (also including its analogous protein N-WASp, 
ubiquitously expressed) (154, 155). Its main function is to mediate signaling of Rho GTPases 
into Arp2/3 complex activation, leading to actin nucleation and branching (156, 157). Under 
steady-state conditions, it exists in an autoinhibited conformation in both the cytoplasm and the 
nucleus (158, 159). 
WASp contains several protein domains, including the WASp homology domain 1; a basic 
region; the GTPase-binding domain (GBD); a proline-rich domain; and the verprolin homology 
domain, cofilin homology domain, acidic region (VCA) domain (Figure 13A) (154). GBD 
binds the VCA domain, resulting in the autoinhibited conformation (158). The WASp-
homology domain 1 binds WASp-interacting protein (WIP), stabilizing the autoinhibited 
conformation and prevents WASp from degradation (160, 161). Upon binding of Rho GTPases 
to GBD, conformational changes are induced, releasing the binding of VCA whereby it can 
bind the Arp2/3 complex (Figure 13B) (158, 162). The structure of WASp is also regulated by 
phosphorylation of tyrosine residues in GBD, which may alter the stability of the autoinhibited 
conformation (163). 
 
Figure 13. WASp function. (A) The inactive, autoinhibited conformation of WASp. (B) Binding of Rho GTPases to the GTP-
ase binding domain (GBD) alters the conformation of WASp, exposing the verprolin homology domain, cofilin homology 
domain, acidic region (VCA) domain for binding of the Arp2/3 complex. This enables the polymerization of actin and branching 
of actin filaments. WH1, WASp homology domain 1; WIP, WASp-interacting protein; G, globular; F, filamentous.  
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WASp is of central importance in the primary immunodeficiencies Wiskott-Aldrich syndrome 
(WAS) and X-linked neutropenia (XLN) (see sections 1.3.1.1 and 1.3.1.2). 
1.2.3 Megakaryoblastic leukemia 1 
MKL1 is a ubiquitously expressed actin monomer-binding protein, mediating its binding via 
an RPEL motif (164, 165). The binding of G-actin to MKL1 inhibits the binding of importins 
to its nuclear localization signal, sequestering MKL1 in its actin-bound state in the cytoplasm 
(Figure 14A) (166). As actin polymerization consumes G-actin, it is released from MKL1, 
whereby MKL1 can translocate to the nucleus and bind serum response factor (SRF) (167); 
MKL1 acts as a transcriptional coactivator of SRF, inducing the transcription of several 
immediate early and cytoskeleton-related genes, including actin (Figure 14B) (168, 169). In 
this way, the dynamics of the cytoskeleton is linked to gene transcription, ensuring enough 
substrate for the rapid turnover of actin filaments and other cytoskeletal components (170). 
MKL1 has been implicated in both cancer and primary immunodeficiency (see section 1.3.1.3). 
 
Figure 14. MKL1 function. (A) MKL1 is sequestered in the cytoplasm by the binding of globular (G)-actin. (B) Actin 
polymerization consumes G-actin, exposing nuclear localization signals (NLS) on MKL1 to the binding of importins, allowing 
MKL1 to translocate to the nucleus. In the nucleus, MKL1 binds serum response factor (SRF), acting as a transcriptional 
coactivator. MKL1-SRF induces the transcription of several immediate early and cytoskeleton-related genes, including actin. 
1.3 PRIMARY IMMUNODEFICIENCY 
Immunodeficiencies are disorders of the immune system where the immune system fails to 
combat infectious agents and/or tumor cells. As opposed to secondary (acquired) 
immunodeficiencies, such as AIDS (due to HIV infection) or immunosuppressive treatment, 
primary immunodeficiencies (PIDs) are inborn diseases due to mutations in genes important 
for normal immune cell function. Generally, PIDs as a group have been viewed as rare diseases, 
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although a recent epidemiological study suggests worldwide overall prevalence might be as 
high as 1 in 1,200 people (171); however, the incidence of each single disease is typically very 
rare, such as WAS (see section 1.3.1.1) with an incidence at the scale of 1–10 in 1,000,000 
(172). 
With recent advances in the research field of PID, it is increasingly clear that there often is an 
overlap in the disease spectrum between immunodeficiency and immune dysregulation: many 
PIDs also include features of autoinflammation, autoimmunity, and/or allergy (173). 
Furthermore, due to deficient immunosurveillance, PIDs carry an increased risk of cancer 
development, particularly lymphomas (174). PID symptomatology and severity differs greatly 
depending on the cell types being affected, ranging from e.g. lethal severe combined 
immunodeficiency (SCID; abolishing development of B and T cells) to IgA-deficiency (the 
most common immunodeficiency with a prevalence of 1 in 600, typically asymptomatic or 
presenting with recurrent mild mucosal infections) (175, 176).  
PIDs may be categorized depending on the affected cell types and on the main pathological 
mechanism of disease. Most PIDs are monogenic and are caused by mutations in genes 
important for immune function; inheritance patterns vary from autosomal dominant, autosomal 
recessive, and X-linked recessive, where autosomal recessive inheritance is the most common 
among PIDs (173). Depending on what cells are affected, PIDs may be classified as combined 
(affecting both B and T cells); predominantly humoral (typically affecting B cells, involving 
impaired antibody responses); immune dysregulation (involving autoimmune features); and 
innate deficiencies (173). 
Management of PID depends of disease phenotype and severity and may be divided into 
symptomatic and curative treatments. For milder PIDs, antibiotic treatments of recurrent 
infections may be sufficient, and some antibody deficiencies can be adequately treated with Ig 
replacement therapy (177). For severe PIDs like SCID, curative treatments involving 
hematopoietic stem cell transplantation (HSCT; typically in the first year of life) are currently 
the main option (178). However, HSCT success is to a large extent dependent on the HLA-
matching between donor and recipient, which may complicate cases where no suitable donor 
is found as the risk for graft-versus-host disease is apparent (179). This risk may be avoided by 
gene therapy, i.e. delivery of healthy gene copies into autologous stem cells that are re-
transfused into the host, essentially curing the disease. Gene therapy using retroviral vectors of 
gene delivery have been used successfully for PIDs such as adenosine deaminase-SCID, X-
linked SCID, chronic granulomatous disorder, and WAS (180). A major pitfall for retrovirus-
based gene therapy is the risk of developing leukemia or myelodysplasia, due to preferential 
genomic incorporation by retroviruses close to proto-oncogenes (181). This may be 
circumvented by the use of artificial endonucleases, a fast-growing field of research which is 
based on non-viral gene-editing, including zinc finger nucleases, transcription activator-like 
effector nucleases and the most recently discovered clustered regularly interspaced palindromic 
repeats (CRISPR)/Cas9 nuclease system. These forms of gene editing diminish the risk of off-
target effects, but are not yet clinically available as treatment for PIDs (180). 
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1.3.1 Primary immunodeficiencies related to cytoskeletal dysregulation 
The cytoskeleton is essential for a wide range of basal cell functions, including migration, 
adhesion, proliferation, and intercellular communication. Some cytoskeletal genes are specific 
to hematopoietic cells, why mutations therein will leave most organs intact except the immune 
system; loss-of-function mutations in ubiquitously expressed genes may be embryonic lethal 
due to the overall importance of the cytoskeleton during development (182). Cytoskeleton-
deficiency PIDs typically affect a broad category of immune cells, thus classify as combined 
or severe combined PIDs (183). Examples of PIDs caused by cytoskeletal dysregulation are 
listed in table 3. 
PID Mutated protein Protein function 
WAS Loss-of-function in WASp Actin polymerization 
XLN Gain-of-function in WASp Actin polymerization 
WIP deficiency Loss-of-function in WIP Regulation of WASp activation and degradation 
DOCK deficiencies Loss-of-function in DOCK2 or 8 Regulating Rho GTPases 
MKL1 deficiency Loss-of-function in MKL1 Sensing actin levels 
Table 3. Primary immunodeficiencies caused by mutations in genes important for cytoskeletal regulation. PID, primary 
immunodeficiency; WAS, Wiskott-Aldrich syndrome; WASp, Wiskott-Aldrich syndrome protein; XLN, X-linked 
neutropenia; WIP, WASp-interacting protein; DOCK, dedicator of cytokinesis; MKL1, megakaryoblastic leukemia-1.  
1.3.1.1 Wiskott-Aldrich syndrome 
WAS is a PID caused by loss-of-function mutations in the gene coding for WASp. Expressed 
uniquely in hematopoietic cells, WASp coordinates cellular signaling to actin polymerization 
and gene transcription, thereby controlling a wide range of cellular functions including 
migration, cell-to-cell communication and differentiation (see section 1.2.2) (154). 
The incidence of WAS is estimated to 1–10 in 1,000,000 births and being an X-linked condition 
in practice almost only affects boys (172). Apart from immunodeficiency with recurrent 
infections, WAS patients typically exhibit other symptoms including hemorrhaging and 
eczema. Microthrombocytopenia (small platelets in low numbers) is present in virtually all 
patients, causing mild to severe hemorrhages in over 80 % of the patient population; 21 % of 
WAS patients die of hemorrhages (184). Eczema afflicts about 80 % of the patient population, 
also facilitating opportunistic infections (184, 185). Moreover, being a distinct sign of poor 
prognosis, malignancies such as leukemia, myelodysplasia and lymphoma develop in 13–22 % 
of the patients and result in up to 25 % of deaths (184, 185). In addition to this, WAS-associated 
autoimmune manifestations are present in 40–72 % of the patients: most commonly in the form 
of autoimmune hemolytic anemia, cutaneous vasculitis, arthritis, and nephropathy, and less 
commonly inflammatory bowel disease, idiopathic thrombocytopenic purpura, and 
neutropenia; all indicating significantly lower survival rates and also increased risk of 
developing tumors (186). 
Diagnosis of WAS is based on clinical parameters, including hemorrhages, infections, and 
eczema, in combination with microthrombocytopenia and a potential family history of WAS 
(187). Currently, the standard treatment of WAS is allogeneic HSCT, which is considered 
curative: the survival rate is up to 80 % after five years of transplantation, the most common 
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complications being infections and graft-versus-host disease (188). Gene therapy for WAS has 
emerged as a potentially successful treatment option, however, correction of thrombocytopenia 
has not yet been sufficiently achieved (189). 
Virtually all hematopoietic cells are affected in WAS (190). Macrophages and dendritic cells 
are unable to form podosomes and display impaired migration and phagocytosis (191-195). B 
cell subsets are affected differently, with a marked reduction of mature B cells (196); WAS 
patients also present with generally low IgM, high IgA and IgE, as well as a broad spectrum of 
autoantibodies (154, 197). T cells are present in low numbers, have altered morphology, and 
proliferate poorly in response to CD3-mediated stimulation (154, 198). Furthermore, the 
immunosuppressive function of Treg cells is impaired in WAS (199). 
1.3.1.2 X-linked neutropenia 
XLN is a rare PID caused by gain-of-function mutations in the gene coding for WASp; 
disruption of the autoinhibited conformation of WASp leads to constitutive activation and a 
marked increase in polymerized actin (200-202). So far, only 20 patients have been described, 
with chronic neutropenia and monocytopenia constituting the major findings, resulting in 
recurrent infections (mainly pneumonia and otitis media) (200-204). Treatments suggested for 
XLN include granulocyte colony-stimulating factor and prophylactic antibiotics, as well as 
antibiotics for any ongoing infections (201, 204). 
Neutrophils in XLN have been shown to be hyperactive and accumulate in tissues (205). NK 
cell numbers are reduced (201, 202). Ig production appears to be normal in patients (200, 202), 
while mouse model in vitro studies have shown impaired B cell proliferation and antibody 
secretion (206). One study found an increase of activated CD8+ T cells in peripheral blood 
(200), however, T cells have also been reported to proliferate normally in response to activation 
(206). Generally increased apoptosis and myelodysplasia have been reported (200, 201, 203, 
206), and lymphocytes display decreased cell spreading and adhesion (206). 
1.3.1.3 MKL1 deficiency 
MKL1 regulates actin levels in the cell by sensing the amount of G-actin in the cytoplasm, 
linking actin dynamics to gene transcription. One case of MKL1 deficiency has been reported 
in a girl born to consanguineous parents, suffering from severe bacterial infections including 
Pseudomonas septic shock, meningitis, and recurring abscesses and ear infections, poorly 
responding to antibiotics (207). She was treated with Ig replacement and put on antibiotic 
prophylaxis (207). Blood tests showed normal lymphocyte numbers and Ig levels, however, T 
cell proliferation was deficient in response to CD3-mediated stimulation and Epstein Barr virus 
(EBV)-transformed B cells displayed impaired migration (207). Neutrophils displayed reduced 
phagocytosis and impaired migration, while dendritic cells displayed impaired cell spreading 
and podosome formation (207). F-actin levels were markedly reduced in both lymphoid and 
myeloid cells (207). 
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1.3.2 LRBA deficiency 
PIDs caused by deficiencies in LPS-responsive beige-like anchor (LRBA) are not technically 
classified as PIDs related to cytosketelal dysregulation: the function of LRBA has not yet been 
fully clarified. However, as described in paper II, LRBA deficiency may present with 
accumulation of a number of different intracellular vesicles, the trafficking of which is known 
to involve the cytoskeleton. 
To this date, 109 patients with LRBA deficiency have been described with varying 
symptomatology, most commonly including autoimmunity, enteropathy, splenomegaly, and 
hypogammaglobulinemia leading to recurrent infections (208, 209). Patients have been treated 
with antibiotics, Ig replacement, immunosuppression, and HSCT (208, 209).  
Cellular deficiencies include reduced Ig production, low numbers and increased apoptosis of 
B cells (208-211); low numbers, increased apoptosis, and deficient activation and proliferation 
of T cells (208, 212); and impaired immunosuppression by Treg cells linked to a decrease in 
CTLA-4 expression (212). Furthermore, LRBA has been shown to colocalize with CTLA-4 in 
endosomal vesicles, and LRBA deficiency leads to reduced surface expression of CTLA-4 due 
to decreased recycling (213). 
 
 

  29 
2 AIMS 
The overall aim of this thesis was to investigate the importance of the cytoskeleton for 
lymphocytes in primary immunodeficiencies. 
Specific aims of the constituent papers: 
Paper I — To investigate the immunological impact of a novel mutation in MKL1 and assess 
its function in B cells from monozygotic triplets with Hodgkin lymphoma. 
Paper II — To investigate the function of LRBA in lymphocytes from a patient with LRBA 
deficiency. 
Paper III — To examine NK cell and T cell function in XLN patients and mouse models. 
Paper IV — To examine the T cell receptor repertoire in WAS mouse models. 
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3 MATERIALS AND METHODS 
The materials used in this thesis include primary cells and established cell lines from patients 
with mutations in MKL1, LRBA, and WASP, as well as immunodeficient NOD-SCID mice and 
mouse models for XLN and WAS. 
Methods used include but are not limited to: flow cytometry; immunofluorescence microscopy; 
western blotting; quantitative reverse transcription polymerase chain reaction (PCR); live-cell 
imaging; transmission electron microscopy; 3H-thymidine incorporation; fluorescent in situ 
hybridization of metaphase telomeres; in vivo tumor cell injection; EBV-transformation of B 
cells; gene targeting; mass spectrometry; imaging flow cytometry; and spectratyping. 
Detailed descriptions of materials and methods used are provided in papers I–III. Materials and 
methods used in paper IV are described in the following section. 
3.1 PAPER IV 
3.1.1 The WASp knockout mouse model 
WASp-/- mice were provided by Drs. Scott Snapper and Frederick Alt of the Department of 
Genetics and Medicine, Harvard Medical School, Boston. WASp-/- mice were bred with 
WASp+/+ BALB/c strain mice (backcrossed 8 generations) to generate WASp-/- mice and wild 
type littermate controls. The mice were bred and maintained under specific pathogen-free 
conditions at the animal facility of the Department of Microbiology, Tumor and Cell Biology 
at Karolinska Institutet, Solna. 
Thymuses from 3–4 weeks old and 7–8 months old mice were excised after euthanasia. Spleens 
were excised from 7–8 months old mice. Three WASp knockout (KO) mice and three wildtype 
(WT) mice were used per experiment. 
3.1.2 Spectratyping analysis of the T cell receptor repertoire 
3.1.2.1 RNA preparation from thymocytes and spleen cells 
Single-cell suspensions were generated from thymuses and spleens, respectively. Cells were 
lysed in 1 ml Trizol for 5 minutes in room temperature. 200 μl chloroform was added to bind 
nucleic acids, and after shaking and incubation in room temperature for 3 minutes, the mixture 
was centrifuged at 12,000 g for 15 minutes at 4 °C. 500 μl of the distinct upper phase, 
containing the nucleic acids, was transferred into a separate tube together with 500 μl of 
isopropanol to precipitate nucleic acids. After shaking and incubation in room temperature for 
10 minutes, the mixture was spun at 12,000 g for 15 minutes at 4 °C, leading to the formation 
of a precipitated RNA pellet on the bottom of the tube. After discarding the supernatant, the 
pellet was washed with 75 % ethanol and spun at 7,500 g for 5 minutes at 4 °C. After discarding 
of the supernatant, the RNA pellet was air-dried for 10 minutes and resuspended in 20 μl 
nuclease-free H2O. The concentration of obtained RNA was estimated using the NanoDrop 
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ND-1000 spectrophotometer (Thermo Scientific, Wilmington, USA). Nucleic acid purity was 
assessed by calculation of 260/280 nm and 260/230 nm wavelength absorbance ratios. 
3.1.2.2 Preparation of complementary DNA from RNA 
Using the Bio-Rad iScript cDNA Synthesis kit (Bio-Rad, Hercules, USA), the RNA template 
was mixed with 4 μl of 5x iScript reaction mix (Bio-Rad), 1 μl iScript reverse transcriptase 
(Bio-Rad) and nuclease-free water to a total volume of 20 μl. The reaction mix was 
subsequently put in a thermal cycler (Bio-Rad) and incubated for 5 minutes at 25 °C, 30 
minutes at 42 °C and 5 minutes at 85 °C. Complementary DNA concentration was estimated 
using the NanoDrop spectrophotometer and the solution was diluted with PBS to acquire a 
concentration of 100 ng/μl. Nucleic acid purity was assessed by calculation of 260/280 nm and 
260/230 nm wavelength absorbance ratios. 
3.1.2.3 Complementary DNA amplification by polymerase chain reaction 
Primers specific for different Vβ-gene segments (Table 4) were purchased from Invitrogen and 
diluted into a concentration of 10 μM. For PCR, a 20 μl mixture of 10 μl GoTaq DNA 
polymerase (Promega, Fitchburg, USA), 1 μl of 100 ng/μl complementary DNA, 1 μl of 10 
μM forward primer, 1 μl of 10 μM reverse primer conjugated to fluorescein amidite 
(Invitrogen), and 7 μl of nuclease-free H2O was prepared for each well of a 96-well PCR plate. 
Each primer was added to two wells to enable calculating the mean of the duplicates and correct 
for eventual pipetting errors. The plates were subsequently put in a thermal cycler (Bio-Rad); 
first incubated for 1 minute at 95 °C; secondly, incubated for 70 seconds at 95 °C, 60 seconds 
at 60 °C and 4 minutes at 72 °C, this second part repeated 40 times; finally, incubated for 10 
minutes at 72 °C and held at 4 °C. 
3.1.2.4 Size separation by electrophoresis  
0.5 μl of each PCR product (the amplified transcript of the V region of the β-chain of the TCR) 
was added to 0.7 μl of 400HD Rox size standard (Applied Biosystems, Foster City, USA) and 
12 μl of deionized formamide (Applied Biosystems). The mixture was subsequently put in a 
thermal cycler (Bio-Rad) at 95 °C for 5 minutes before being run in an ABI Prism 3730 DNA 
Sequencer (Applied Biosystems). DNA fragments were separated by electrophoresis according 
to their size and presented in a spectratype densitogram. 
3.1.2.5 Statistical analysis 
Fragment analysis data from the ABI Prism 3730 DNA Sequencer was analyzed using the 
PeakScanner software (Applied Biosystems). Duplicates means for each segment were 
calculated and plotted in GraphPad Prism (GraphPad Software, La Jolla, USA). Nucleotide 
size and area under curve for each segment were added and nonlinear regression analyses 
were performed in order to quantify goodness of fit, yielding an R2 value (0 ≤ R2 ≤ 1). WT 
and KO values were analyzed with Student’s t-test for each segment. A p-value of < 0.05 was 
considered significant. 
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Primer sequence in nucleotides Primer specificity Notes 
TCACTGATACGGAGCTGAGGC TCR Vβ1  
GCCTCAAGTCGCTTCCAACCTC TCR Vβ2  
CACTCTGAAAATCCAACCCAC TCR Vβ3  
ATCAAGTCTGTAGAGCCGGAGGA TCR Vβ4  
CTGAATGCCCAGACAGCTCCAAGC TCR Vβ5  
AAGGTGGAGAGAGACAAAGGATTC TCR Vβ12.1  
CATTATGATAAAATGGAGAGAGAT TCR Vβ12.2 Non-functional in BALB/c mice 
AGAAAGGAAACCTGCCTGGTT TCR Vβ12.3 Non-functional in BALB/c mice 
TGCTGGCAACCTTCGAATAGGA TCR Vβ13.1  
CATTATTCATATGGTGCTGGC TCR Vβ13.2 Non-functional in BALB/c mice 
CATTACTCATATGTCGCTGAC TCR Vβ13.3  
AGGCCTAAAGGAACTAACTCCCAC TCR Vβ14 Non-functional in BALB/c mice 
GATGGTGGGGCTTTCAAGGATC TCR Vβ15  
GCACTCAACTCTGAAGATCCAGAGC TCR Vβ16  
TCTCTCTACATTGGCTCTGCAGGC TCR Vβ17  
CTCTCACTGTGACATCTGCCC TCR Vβ19  
CCCATCAGTCATCCCAACTTATCC TCR Vβ20  
CTGCTAAGAAACCATGTACCA TCR Vβ21 Non-functional in BALB/c mice 
TCTGCAGCCTGGGAATCAGAA TCR Vβ23  
AGTGTTCCTCGAACTCACAG TCR Vβ24  
CCTTGCAGCCTAGAAATTCAGT TCR Vβ26  
TACAGGGTCTCACGGAAGAAGC TCR Vβ29  
CAGCCGGCCAAACCTAACATTCTC TCR Vβ30  
ACGACCAATTCATCCTAAGCAC TCR Vβ31  
CTTGGGTGGAGTCACATTTCTC TCR Cβ Conjugated to FAM 
Table 4. Primer sequences used for the amplification of Vβ segments. TCR, T cell receptor; FAM, fluorescein amidite. 
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4 RESULTS AND DISCUSSION 
4.1 INCREASED MKL1 ACTIVITY PARTICIPATES IN B CELL 
TRANSFORMATION AND HODGKIN LYMPHOMA PATHOGENESIS 
The actin-sensing protein MKL1 was initially described as part of a fusion protein in 
megakaryoblastic leukemia (214, 215). Dysregulated MKL1 expression and activity have been 
implicated in both primary immunodeficiency and cancer (207, 216-218). Recently, two 
monozygotic triplets with Hodgkin lymphoma were described, diagnosed in 1985 and 2008, 
respectively (219). Blood samples from these patients and their undiagnosed triplet sibling 
were analyzed using microarray comparative genomic hybridization, identifying a 15–31-kb 
deletion in intron 1 of MKL1 (219). The immune status of the triplets and expression levels 
of MKL1 were not known. In paper I, we sought to investigate the impact of the MKL1 
mutation on B cell function and Hodgkin lymphoma pathogenesis and generated EBV-
transformed lymphoblastoid cell lines (LCLs) from all three triplets and two matched 
controls.  
MKL1 protein expression was increased in primary cells from the triplets with Hodgkin 
lymphoma (HL1 and HL2) and the undiagnosed triplet (HL0), as assessed by flow cytometry. 
HL0 LCLs were found to have higher MKL1 mRNA and MKL1 protein expression than 
HL1-2 and controls, as assessed by quantitative reverse transcription PCR and western 
blotting, respectively. MKL1-SRF induces transcription of several genes, including SRF and 
ACTB (168, 169). To examine MKL1 activity in LCLs from the triplets and controls, we 
measured mRNA expression of MKL1-dependent genes SRF and ACTB by quantitative 
reverse transcription PCR and found that it correlated to MKL1 mRNA expression: HL0 LCLs 
displayed the highest expression for both MKL1-dependent genes. Flow cytometry-assessed 
G-actin expression was increased in HL0 LCLs as compared to HL1-2 and controls. F-actin 
was increased in primary B cells from HL2, and in primary monocytes from all triplets. 
To investigate morphological and functional differences associated to increased MKL1 
expression, we examined cell spreading, aggregation, proliferation, genomic stability, and in 
vivo tumor formation. Actin-dependent cell spreading was increased in HL0 and HL1 LCLs, 
as assessed by immunofluorescence microscopy, and interference reflection microscopy 
showed larger adhesion areas for HL0 LCLs. HL0 LCLs in culture aggregated less, associated 
to a decrease in adhesion receptor CD11a. Primary B cells from all triplets proliferated more 
than control cells as measured by flow cytometry-assessed expression of proliferation marker 
Ki-67. 3H-thymidine incorporation assessment showed higher DNA synthesis in HL0 LCLs as 
compared to controls, also having a larger proportion of cells in S or G2/M phase and cells 
with more than 4n DNA content. HL0 and HL1 had an increased proportion of cells with 
more than 46 chromosomes, as assessed by fluorescent in situ-hybridization on metaphase 
telomeres. When injected into immunodeficient NOD-SCID mice, control LCLs failed to 
form tumors while HL0 LCLs formed large tumors with distinct angiogenesis in vivo. 
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To investigate the causality between increased MKL1 activity and the observed phenotype 
of HL0 LCLs, we sought to revert its phenotype with a small molecule inhibitor of MKL1 
(220, 221). CCG-1423-treated HL0 cells displayed a dose-dependent lowering of MKL1 and 
SRF expression, as well as decreased cell spreading, aggregation, and proliferation. In vivo 
tumors of HL0 LCLs were suppressed by repeated intratumoral CCG-1423 injections.  
These results indicated that the intronic deletion in MKL1 led to increased MKL1 expression 
and activity, as well as malignancy-associated features of cytoskeletal derangement, increased 
proliferation, genomic instability, and tumor growth in vivo. Curiously enough, these features 
were most pronounced in the undiagnosed (and thus untreated) triplet HL0, while triplets HL1 
and HL2 mostly resembled controls. This led us to reason that HL0 may be in a premalignant 
state, acting as an untreated control compared to triplets HL1 and HL2. As the intronic deletion 
in MKL1 was found to be heterozygous (Figure S2, paper I), increased MKL1 expression in 
cells may have been a stochastic process, providing selective advantage for cells expressing the 
allele bearing the intronic deletion. The low penetrance of the mutation may represent a slow 
build-up of the premalignant cell population, potentially reset by chemotherapy, which would 
explain the mild and varying phenotype of HL1 and HL2 cells. 
As MKL1 has been implicated in PID (207), and PIDs convey a higher risk of cancer 
development (174), the cause of Hodgkin lymphoma development in the triplets with the 
intronic deletion in MKL1 may have been both intrinsic to B cells and extrinsic as by deficient 
immunosurveillance. However, we found no signs of immunodeficiency in the triplets, as 
assessed by infection history, leukocyte subset numbers, or mitogen stimulation of 
lymphocytes, suggesting that the development of Hodgkin lymphoma may primarily have been 
cell-intrinsic. In breast cancer and melanoma cell lines, MKL1 has been shown to be required 
for cancer cell adhesion, spreading, invasion, and motility, and overexpression of MKL1 
increased metastatic potential (216). In hepatic and breast cancer cell lines deficient of the 
tumor suppressor deleted in liver cancer 1, MKL1 mediated increased migration, proliferation, 
and cell growth (218). MKL1 also mediates the transformation of breast cancer cells into being 
independent of hormone receptor signaling, a sign of increased malignancy (217). We searched 
the R2 Oncogenomics Platform (222) for MKL1 and found increased expression in Hodgkin 
lymphoma and lymphomas in general (Figure S9, paper I). SRF has been shown to mediate 
signaling downstream of the BCR (223), suggesting that increased MKL1-SRF activity as seen 
in our patients drives B cell activation and maturation. Altogether, these findings by us and 
others support the notion that Hodgkin lymphoma developed as a result of increased MKL1 
expression in the triplets with the intronic deletion in MKL1. 
4.2 LRBA DEFICIENCY LEADS TO VESICLE ACCUMULATION AND ALTERED 
LIPID METABOLISM 
Patients with LRBA deficiency suffer from a syndrome with features ranging from PID (similar 
to common variable immunodeficiency) to autoimmunity (209). The function of LRBA is yet 
to be clarified, but its protein domains are also found in other proteins involved in vesicle 
trafficking and membrane dynamics (224). We obtained blood and skin samples from a female 
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LRBA-deficient patient presenting at age 4 with lymphadenopathy, splenomegaly, 
neutropenia, and thrombocytopenia, as well as autoimmune enteropathy; over time she 
developed several deep infections (225). In paper II, we aimed to examine the role of LRBA 
in vesicular dynamics and generated cell lines of patient fibroblasts and EBV-transformed B 
cells (LCLs), as well as CRISPR/Cas9 LRBA KO Jurkat T cells. 
As lack of LRBA expression previously was described in LCLs from this patient (225), we 
confirmed that patient fibroblasts also lacked LRBA expression, assessed by 
immunofluorescence microscopy and flow cytometry. Decreased LRBA expression was also 
confirmed in CRISPR/Cas9 LRBA-targeted Jurkat T cells generated by us. LRBA has 
previously been described to prevent degradation of CTLA-4 (213). LRBA-/- Jurkat T cells 
expressed lower CTLA-4 than control cells, and while control Jurkat T cells transduced with 
CTLA-4 recycled CTLA-4 efficiently to the cell surface, CTLA-4-transduced LRBA-/- Jurkat 
T cells failed. These results show that both patient B cells and fibroblasts indeed lack LRBA, 
and that the LRBA KO in Jurkat T cells was successful in generating a phenotype similar to 
previously described LRBA-deficient T cells. 
In another previously described patient with LRBA deficiency, the number of autophagosomes 
was increased in B cells as measured in transmission electron micrographs (210). By flow 
cytometry, we found that LCLs from our patient had a higher expression of autophagosomes 
than control cells, as detected by a cationic amphiphilic tracer dye. Autophagic flux was 
increased in patient fibroblasts, as measured by western blotting. However, when examining 
patient and control fibroblasts by transmission electron microscopy, differences in numbers of 
autophagosomes and lysosomes in fibroblasts did not reach statistical significance. This may 
be related to the relatively small sample size or suggest that LRBA-deficient B cells were more 
prone than fibroblasts to accumulate autophagosomes. 
Patient LCLs and fibroblasts accumulated endosomes and lysosomes, as assessed by 
immunofluorescence microscopy. The accumulation of lysosomes in patient fibroblasts was 
confirmed in several settings: in untreated cells; with stimulation with serum starvation, LPS, 
and bafilomycin A1 to induce autophagy; and with stimulation with oleic acid to induce lipid 
body formation (see below). Flow cytometric analysis also showed an increase in lysosomes 
in unstimulated patient fibroblasts. No apparent difference was detected between LRBA-/- and 
control Jurkat T cells. 
When examining Jurkat T cells by transmission electron microscopy, we found that LRBA-/- 
cells had an increase in both size and number of lipid bodies, with and without serum starvation. 
This led us to investigate the lipid compartment in fibroblasts as well and we found an increase 
in lipid bodies in patient fibroblasts, corroborated by two different immunofluorescent markers 
for lipids. Oleic acid was added to the fibroblasts to induce lipid body formation. Patient 
fibroblasts did further not increase their amount of lipid bodies by oleic acid treatment; control 
fibroblasts increased their amount of lipid bodies to match patient levels. The finding that the 
difference between unstimulated and stimulated fibroblasts was significantly large for control 
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fibroblasts but not for patient fibroblasts indicates that lipid body formation in untreated patient 
fibroblasts was already induced to a high degree by lack of LRBA. 
To examine the overall lipid composition in LRBA-deficient patient cells, we used liquid 
chromatography combined with mass spectrometry to identify 10 different lipid classes. Patient 
and control fibroblasts were either untreated, serum starved, or starved and refed with serum. 
By unsupervised multivariate statistical analysis, we found that while starved control 
fibroblasts clustered with untreated control and patient fibroblasts, starved patient fibroblasts 
clustered with refed starved control and patient fibroblasts. When analyzing individual lipid 
classes, we found that the latter cluster had an increase of several lipid classes, including 
phosphatidylcholine and sphingomyelin. Pairwise analysis showed that patient fibroblasts 
responded to starvation by the increase of several lipid metabolites, while control fibroblasts 
did not respond to this stimulation. When refeeding starved fibroblasts with serum, patient cells 
did not further increase their lipid content, however, starved control cells responded to 
refeeding with an increase in several lipid metabolites. These findings suggest that patient 
fibroblasts have an altered response to starvation-induced stress, increasing their biogenesis of 
several lipid metabolites. 
In this study, we have examined LCLs and fibroblasts from a female patient with LRBA 
deficiency, and LRBA-/- Jurkat T cells. A limiting factor for has been the poor viability of 
patient LCLs in culture: they rapidly died, why the collection of the required number of cells 
for several experiments has been hampered. LRBA-deficient B cells have previously been 
described as more prone to undergo apoptosis (210), why this may have been the reason for 
poor LCL viability in our experiments. To combat this, we took the approach to use fibroblasts 
for a large part of the experiments: primary fibroblast cell lines are stable, easy to keep in 
culture and convey less confounding factors than transformed cell lines; furthermore, they are 
easily obtained from skin biopsies (226, 227). The drawback of this approach is that some 
phenotypes unique to immune cells may not be present in fibroblasts. 
We found that several different intracellular vesicles accumulated in LRBA-deficient patient 
cells, including lysosomes. Dysregulation of lysosomes is found in a group of diseases called 
lysosomal storage disorders, some of which involve immunodeficiency features with recurrent 
infections (228): α-mannosidosis type II, caused by mutations in MAN2B1 (229); Griscelli 
syndrome type 2, caused by mutations in RAB27A (230); and Chédiak-Higashi syndrome, 
caused by mutations in LYST (231). LYST has a BEACH protein domain that may mediate 
vesicle dynamics, a domain also found in LRBA (224), supporting our findings of vesicle 
dysregulation in LRBA deficiency.  
Lysosomes are important in the sensing of intracellular nutrients, and may play a role in lipid 
metabolism by the induction of lipophagy during cell stress such as serum starvation (232). 
This may explain our findings of lipid body accumulation and alterations of the lipid class 
composition in LRBA-deficient cells. We argue that the accumulation of endosomes, 
lysosomes, autophagosomes and lipid bodies may impair the survival and function of immune 
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cells, leading to the immunodeficiency and autoimmunity present in patients with LRBA 
deficiency.  
4.3 NK CELLS AND T CELLS IN XLN PATIENTS AND MOUSE MODELS ARE 
HYPERACTIVE  
XLN is caused by activating mutations in WASp, presenting with neutropenia and 
immunodeficiency as well as an increased risk of myelodysplasia (200-204). Cytogenetic 
analysis of both XLN patients and mouse models has shown increased genomic instability with 
increased DNA content, tetraploidy, and chromosomal breaks (206, 233). XLN T cells have 
been shown to proliferate normally, however, one study found an increase of CD8+ T cells in 
peripheral blood (200, 206). XLN NK cells are low in numbers (201, 202). NK cells and T 
cells are crucial to tumor immunosurveillance, and in WASp deficiency (WAS), NK cells and 
T cells are hyporesponsive and immune synapse formation is impaired (234, 235). NK cell and 
T cell responsiveness to tumors in XLN, however, remains unknown. To investigate this, in 
paper III we examined NK cells and T cells from XLN patients and two different mouse 
models with WASp mutations corresponding to those found in patients (WASpL272P and 
WASpI296T).  
Using in vivo imaging, we found that the rejection of injected YAC-1 T cell lymphoma cells 
was similar in WT and WASpL272P mice. In vivo NK cell-mediated rejection of β2 
microglobulin-negative splenocytes (lacking MHC class I molecules) was similar in WT and 
WASpL272P mice at 24 hours, but higher in WASpL272P mice at 8 and 48 hours after injection. 
In vitro activation of NK cells with antibodies to the activating NK cell receptors NKp46 and 
NK1.1 led to IFN-γ production and degranulation in WT, WASpL272P, and WASpI296T mice. 
WT, WASpL272P, and WASpI296T responded similarly in vitro to activation by YAC-1 cells. 
These results show that NK cells in XLN mouse models were not hyporesponsive as in WAS, 
but rather hyperactive in their rejection of tumors. 
To investigate whether this increased activity was related to any developmental aberrations, we 
examined the education, maturation, and receptor repertoire of NK cells in WT, WASpL272P, 
and WASpI296T mice. There were no differences in NK cell numbers or in surface markers for 
education and maturation stages. The proportion of the main classes of NK cell inhibitory 
receptors and the amount of different receptor classes per cell was similar in WT, WASpL272P, 
and WASpI296T mouse models. These results indicated that the development of NK cells in 
XLN proceeded normally. When examining the individual expression of several different 
inhibitory and activating receptors, levels were similar in all three models except for the 
inhibitory NK cell receptor KLRG1: WASpL272P and WASpI296T expressed significantly lower 
KLRG1 than WT; this result contrasts the increase of KLRG1 in WASp deficiency (236). 
As mobilization of actin is important for immune synapse formation, we examined NK cell 
actin dynamics in the XLN mouse models. Total F-actin expression was normal in WASpL272P 
and WASpI296T as compared to WT. When incubated with YAC-1 cells, WT, WASpL272P, and 
WASpI296T NK cells polarized actin and formed similar immune synapses to YAC-1 cells, as 
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assessed by imaging flow cytometry. When adhered to glass surfaces coated with antibodies to 
NKp46, NK cells polarized actin similarly in all three models, as assessed by stimulated 
emission depletion microscopy. However, WASpL272P and WASpI296T managed to polarize 
actin to the glass surface even without activation of NKp46. These results suggest that XLN 
NK cells are hyperactive in the way that they can polarize actin without activation signals. 
Flow cytometric analysis of CD8+ T cells from WT, WASpL272P, and WASpI296T mice showed 
similar degranulation and IFN-γ production in response to CD3 stimulation in all three models. 
However, while CD4+ T cells from WASpI296T and WT mice were similar in degranulation 
and IFN-γ production, these processes were impaired in WASpL272P CD4+ T cells. When 
analyzed by imaging flow cytometry, both CD8+ and CD4+ T cells in WASpL272P and 
WASpI296T polarized actin similarly to WT in response to CD3 and CD28 stimulation. 
However, when incubated with A20 B cell lymphoma cells coated with anti-CD3 and anti-
CD28, WASpL272P T cells displayed a higher killing rate in vitro than WT T cells as assessed 
by live-cell imaging.  
As opposed to XLN mouse models, XLN patients have lower numbers of NK cells (201, 202). 
To investigate whether these patient NK cells respond normally, we examined peripheral blood 
mononuclear cells from two XLN patients (bearing a L270P mutation corresponding to the 
L272P mutation in mice) and their mother and sister, heterozygotic carriers for the mutation, 
as well as two healthy controls. Flow cytometry analysis showed significantly smaller 
populations of CD56bright and CD56dim NK cells in the XLN patients. To examine tumor 
responsiveness, XLN patient NK cells were incubated with K562 myelogenous leukemia cells 
and analyzed by flow cytometry: degranulation was decreased in XLN NK cells but IFN-γ 
production was similar to controls and carriers. XLN patient NK cells responded normally to 
receptor-independent stimulation by phorbol myristate acetate and ionomycin. As in 
WASpL272P and WASpI296T mice, the XLN patients displayed lower KLRG1 expression. 
Granzyme B expression was higher in XLN patients. 
When examining XLN patient T cells by flow cytometry, we found an increase in CD4+ 
CD8low cells as compared to controls and carriers. KLRG1 expression was higher in XLN 
patient T cells, as opposed to the lower expression found in NK cells. Granzyme B expression, 
however, was high in XLN patient T cells as well, similar to NK cells. As increased expression 
of KLRG1 and granzyme B may represent exhaustion in T cells (35), we examined the response 
of CD8+ and CD4+ T cells to phorbol myristate acetate and ionomycin but found that the 
proportional distribution of activated T cells in XLN patients was similar to controls and 
carriers. 
These results show that the function of NK cells and T cells with activating mutations in WASp 
contrasts WASp-deficient NK cells and T cells. In summary, NK cells in XLN display normal 
to increased tumor killing (in mice), a decrease in the exhaustion marker KLRG1 (in patients 
and mice), increased granzyme B expression (in patients), and polarization of actin without 
stimuli (in mice). T cells in XLN show overall normal degranulation and IFN-γ production (in 
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mice), increased KLRG1 and granzyme B expression (in patients), and increased tumor killing 
(in mice). 
Some results were inconsistent between different XLN models. The increase of YAC-1 killing 
and β2 microglobulin-negative splenocyte rejection in XLN mice and concomitant decrease of 
degranulation in XLN patients in response to K562 cells may reflect different response 
pathways triggered by the different tumor models. To investigate this further, the tumor killing 
assays for XLN patients and mice should include the same tumor cells. Furthermore, the normal 
degranulation and IFN-γ production in CD8+ T cells in both XLN mouse models and in 
WASpI296T CD4+ T cells contrasted the decrease in WASpL272P CD4+ T cells. This may reflect 
T cell subset-specific modes of actions of the I269T and L272P mutations.  
KLRG1 is an inhibitory NK cell receptor also associated to lack of proliferative capacity in T 
cells (33, 35), and increased KLRG1 expression has been described in WASp-deficient NK 
cells (236). Our findings of lower KLRG1 expression in XLN NK cells may indicate that these 
cells are hyperactive due to less inhibitory signals, although NK cells expressing KLRG1 have 
been linked to improved tumor immunosurveillance (237). The increase of KLRG1 in XLN 
patient T cells may indicate exhaustion, however, this is contradicted by our findings of normal 
receptor-independent responses. These findings illustrate the need for more studies on the 
connection between WASp, actin polymerization, and KLRG1 expression. 
In summary, NK cells and T cells in XLN do not seem to be deficient in their tumor killing 
capacity, suggesting that the increased risk of myelodysplasia and malignancy observed in 
XLN patients is caused by cell-intrinsic aberrations rather than by deficient tumor 
immunosurveillance. 
4.4 THE T CELL RECEPTOR REPERTOIRE IN WISKOTT-ALDRICH 
SYNDROME IS INCREASINGLY PERTURBED WITH AGE 
Loss-of-function mutations in WASp result in WAS, presenting with hemorrhages, infections, 
and eczema (184, 185). T cells in WAS are fewer, have altered morphology, and proliferate 
poorly to stimulation (154, 198). Furthermore, Treg function is impaired and B cells produce 
autoantibodies, potentially leading to autoimmune responses (197, 199). However, it has 
remained unknown if effector T cells in WAS can be autoreactive. Impaired distribution of the 
TCR repertoire has been correlated to the development of autoimmunity in PID and other 
diseases (238, 239). The aim in paper IV was to examine the naïve TCR repertoire in young 
mice (before the development of autoimmunity) and older mice to understand if WASp-
deficient T cells undergo normal selection and differentiation. To investigate this, we obtained 
thymocytes and spleen T cells from WT and WASp KO mice. 
In young (3–4 weeks old) mice, the thymocyte TCR repertoire in WASp KO mice was 
indistinguishable from WT mice (Figure 15), indicating normal thymic output in WASp-
deficiency. When examining older (7–8 months old) mice, the thymocyte TCR repertoire 
displayed impaired diversity, most pronounced in WASp KO mice (Figure 1D-F, paper IV). 
Furthermore, the spleen T cell TCR repertoire showed signs of clonal expansion in WASp KO 
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mice (Figure 16), however, differences between WASp KO and WT in the overall spleen T 
cell TCR repertoire did not reach clinical significance (Figure 1F, paper IV). 
 
Figure 15. The thymocyte TCR receptor repertoire in young wildtype and WASp knockout mice. The distribution of 
thymocyte TCRs with the Vβ1 segment shown here (representative graphs). R2 values indicate goodness of fit. WT, wildtype; 
KO, knockout. 
Using the same technique of spectratyping, the first study of the TCR repertoire in WAS 
patients showed intact diversity in patients younger than 15 years of age and impaired diversity 
in older patients (240). However, later studies have shown oligoclonal repertoires also in young 
WAS patients, both using spectratyping and next generation sequencing (241-243). 
Furthermore, clonal expansions were identified in CD4+ memory T cells as well as in CD8+ 
naïve and memory T cells (243). The cause of the skewed TCR repertoire in WAS patients has 
been unknown, but it has been speculated to reflect impaired thymic output, decreased 
peripheral T cell survival, or chronic exposure to infections (243, 244). 
 
Figure 16. Clonal expansion of spleen T cells in an old WASp knockout mouse. The distribution of spleen T cells TCRs 
with the Vβ1 segment shown here. Arrowhead indicates clonal expansion, defined by an area under curve ≥ 60 % of the 
adjacent peaks. The R2 value indicate goodness of fit. KO, knockout. 
Our study based on WASp KO mouse models provided a unique advantage in that we were 
able to keep the animals free from infection, a condition not possible to maintain for patients, 
thus indicating that the clonal expansion observed in WASp KO spleen T cells from old mice 
may have been triggered by autoantigens rather than infections. Furthermore, thymic output 
could be assessed in our model by the selective examination of thymocytes in young and old 
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mice: our results show intact thymic output in young mice and suggest that the dependency on 
WASp to generate a diverse TCR repertoire increased with age. This contradicts the hypothesis 
raised by Wada et al. that skewed repertoires in older patients was not due to impaired thymic 
output (240). With increasing age, physiological involution of the thymus may indeed restrict 
the TCR repertoire by reduced thymic output and compensatory homeostatic proliferation 
(245). Increased homeostatic proliferation is seen in WAS (246), and has generally been 
associated to development of autoimmunity due to selective pressure on T cells expressing 
TCRs with high affinity to self-peptide-MHC molecules (247-249). These findings may 
explain the further increased skewing of the TCR repertoire in old WASp KO mice as 
compared to WT mice. 
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5 CONCLUSIONS AND FUTURE OUTLOOK 
In this thesis, I have investigated the role of dysregulated actin and intracellular vesicles in 
lymphocytes and other cells in PID and cancer. 
In paper I, we present a unique model to investigate the role of MKL1 in the development of 
Hodgkin lymphoma. We examined B cells from three monozygotic triplets with an intronic 
deletion in MKL1, leading to increased MKL1 expression. B cells from the two triplets 
diagnosed with and treated for Hodgkin lymphoma presented with variable phenotypes, while 
B cells from the third triplet presented with classical hallmarks of cancer cells: 
hyperproliferation, dysregulated cytoskeleton, genomic instability, and formation of tumors 
with induction of angiogenesis. This suggested that this triplet represented a premalignant 
phenotype, acting as an untreated control to the two other triplets. The correlation of MKL1 
expression to increased MKL1-SRF-dependent gene transcription, reversion of the phenotype 
by the use of a small molecule inhibitor of MKL1, and evidence of MKL1 involvement in 
several other cancer models, suggest a role of MKL1 in the development of Hodgkin 
lymphoma. 
In paper II, we examined cells from an LRBA-deficient patient presenting with 
immunodeficiency and autoimmunity. We show that patient cells accumulated vesicles 
including endosomes, lysosomes, autophagosomes, and lipid bodies. Furthermore, lipid 
metabolism was altered in patient cells in response to starvation. Our results suggest that LRBA 
deficiency conveys dysregulated responses to cell stress, and that the accumulation of vesicles 
may impair the survival and function of immune cells, leading to the immunodeficiency and 
autoimmunity present in patients with LRBA deficiency. 
In paper III, we examined NK cells and T cells in XLN patients and mouse models. As 
opposed to the hyporeactive phenotype in WAS, XLN NK cells and T cells displayed normal 
to increased tumor killing, decreased expression of the exhaustion marker KLRG1, increased 
granzyme B expression, and polarization of actin without stimuli. These results suggest that 
the increased risk of myelodysplasia observed in XLN is caused by cell-intrinsic aberrations 
rather than by deficient tumor immunosurveillance. 
In paper IV, we show that the distribution of the TCR repertoire is skewed in thymocytes and 
spleen T cells in old WASp KO mice. As young WASp KO mice showed a normal TCR 
repertoire distribution, these results suggest that the dependence on WASp for thymic output 
and the generation of a diverse TCR repertoire increases with age. Furthermore, clonal 
expansions in spleen T cells in the absence of infections suggested that autoantigens may 
trigger the development of a skewed TCR repertoire. 
In summary, this thesis provides evidence for the role of dysregulated cytoskeletal responses 
in the development of PID and cancer. Increased actin by mutated MKL1 and in XLN leads to 
aberrant activation of B cells, NK cells, and T cells. Decreased actin in WAS leads to disruption 
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of the TCR receptor repertoire. LRBA deficiency leads to vesicle dysregulation in B cells and 
fibroblasts. 
Commercially available small molecular inhibitors of actin polymerization and MKL1 activity 
could potentially be used as therapeutic agents in diseases with increased actin responses. CK-
666 and CK-689 are inhibitors of the Arp2/3 complex (250) and wiskostatin is an inhibitor of 
WASp and N-WASp (251). CCG-1423 as well as the more recently described CCG-100602, 
CCG-203971, and CCG-222740 inhibit MKL1 activity (220, 252, 253). However, cytotoxicity 
may be a prominent side-effect of these small molecular inhibitors, why further studies are 
needed to optimize their efficacy and safety before they can be used clinically. 
Increased MKL1 expression has been shown by us and others to be involved in cancer 
development. However, at this point, it is unknown whether the level of MKL1 expression 
correlates to disease severity or prognosis, and if it is restricted to certain kinds of cancer cell 
types. Further studies are warranted to investigate MKL1 expression levels in different stages 
and types of cancer. Depending on the result of these studies, screening for MKL1 as a cancer 
marker could potentially be used in the clinic to determine which examinations or treatments 
to choose for individual patients.  
Dysregulation of lipid metabolism has been shown for several diseases, including lysosomal 
storage diseases such as Niemann-Pick disease type C1 or Gaucher disease caused by 
enzymatic deficiencies in lipid metabolism (254, 255). For these diseases, enzyme replacement 
therapies have been proved successful (256, 257), why these readily available compounds may 
be used in studies on lipid dysregulation in LRBA deficiency. Enzymes involved in the 
metabolism of sphingomyelin and phosphatidylcholine would be of particular interest, as we 
observed accumulation of these in LRBA-deficient cells subjected to starvation-induced stress. 
The advancement of DNA sequencing technologies has provided sophisticated means of 
identifying potential pathogenic mutations in the study of PIDs and other genetical diseases. 
However, regardless of how exact and readily available these techniques may become, the 
clinical relevance of a given mutation can not be determined without functional laboratory 
studies.  
Studies of PIDs are highly important models to investigate the function of individual proteins 
in the immune system. And as PIDs generally are monogenic, in this aspect they are in practice 
comparable to knockout mouse models. However, a limiting factor in the study of human PIDs 
is the scarcity of material, due to the generally extremely low prevalence of each single PID. 
Furthermore, as HSCT early in life typically is required for severe PIDs, study material such 
as blood samples would have to be obtained before treatment, and there is a risk that the 
obtainment of large samples may be unethical and harmful to the often very young patients. 
This emphasizes the continued relevance of mouse models in research on PIDs and 
immunology in general, as a means of providing material and in vivo systems to understand the 
complexity of the immune system in health and disease. However, it should be noted that while 
mouse models have been essential for human immunological research, interspecies differences 
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may still be significant, and further increased by the artificial pathogen-free conditions most 
research mice are kept under (258-260). Altogether, future research on PID will likely require 
a well-balanced combination of mouse models, patient material, and genetically engineered 
human cells. 
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